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Over the past decade the most exciting surgical advance in the management of breast
cancer has been the introduction of sentinel lymph node biopsy. The American Society
of Clinical Oncology (ASCO) published guidelines on the use of sentinel lymph node
biopsy in 2005 suggesting that it was a safe and accurate way to stage the axilla in
patients with early breast cancer and who were clinically node negative and therefore an
appropriate alternative to axillary node clearance in these patients (Lyman et al. 2005).
Sentinel node biopsy has now become the standard of care in many centres worldwide
however in the United Kingdom only a minority of breast surgeons are currently
performing the technique.
In addition to providing a less morbid procedure for the patient, sentinel node biopsy can
increase the detection ofmetastatic disease leading to a potential 'stage shift'. The
technique offers the opportunity to detect smaller disease foci in the sentinel node
because one or a few sentinel nodes can be more intensively examined than an entire
clearance specimen. There is some evidence that micrometastases diagnosed by serial
sectioning or immunohistochemistry lead to poorer survival rates however there remains
some controversy about this and they are not as yet a required part of sentinel lymph node
evaluation as laid down in the ASCO guidelines. Molecular techniques such as RT PCR
can identify isolated tumour cells although the clinical significance of these is unknown.
The aim of this study was to use the reverse transcription polymerase chain reaction (RT
PCR) to assess sentinel lymph nodes from 2 groups of breast cancer patients. Group 1
consisted of 54 patients from whom 68 half sentinel nodes had been obtained while group
2 consisted of 50 patients from whom 60 sentinel nodes were obtained. Three putative
breast cancer antigens or 'markers' were identified in the sentinel nodes, cytokeratin 19
(CK 19), mucin 1 (MUC 1) and carcinoembryonic antigen (CEA). The expression rates
of these markers were compared with each other and with the conventional H&E
histology of these nodes. In particular the technique was used and compared in the 2
groups where half of each sentinel node was examined by RT PCR in group 1 and a 4pm
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section was cut from each sentinel node and examined by RT PCR in the sentinel nodes
from group 2. There are no reports in the literature where RT PCR has been used to
evaluate different amounts of sentinel lymph node tissue.
The initial hypotheses of this study were first that the expression rates of the 3 markers,
as determined by RT PCR, would correlate more closely with conventional histology
than would the expression of any individual marker. Second, this correlation would be
closer when more of the sentinel node, ie half a node compared to a 4pm section, was
processed for RT PCR. Third, the number of histologically negative sentinel lymph
nodes upstaged by RT PCR would therefore be greater when half nodes were processed.
RNA extraction and subsequent RT PCR was performed on one half of each of 68
sentinel nodes and from a single 4pm section cut from each of 60 sentinel nodes.
The sentinel nodes harvested from the patients in group 1 were performed using
radioactive colloid in 56% of cases and blue dye in all cases. In group 2, a total of 65
procedures were carried out and a sentinel node was identified in 50 patients, giving a
detection rate of 77%. The sentinel node biopsies performed in group 2 were all done
using a combination of radioactive colloid and blue dye. A pre-operative scan was
performed in all 65 cases and was positive in only 19 of these (29.2%). The combined
false negative rate for both groups, based on H&E histology, was 25.7% (19/65 patients).
The results showed that there was poor correlation both between the marker expression
and H&E histology and between the different markers themselves in individual sentinel
nodes in both groups 1 and 2. Disappointingly, only one third or less of the nodes from
each group displayed the same expression patterns for all 3 markers. Contrary to what
had been expected, the expression rate did not seem to depend on the proportion of the
node that was examined by RT PCR. More nodes however were upstaged when half the
node was examined by RT PCR rather than when only a 4pm section was examined.
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While the association ofmarker expression with H&E histology was poor, a strong
association between CK 19 expression and Nottingham Prognostic Index (NPI) was
found in both groups of patients. This suggests that both the size and grade of the tumour
as well as extent of lymph node involvement may contribute to the likelihood of CK 19
expression in the sentinel node. There was no such association for MUC 1 or CEA.
In conclusion, even when the expression rates of CK 19, MUC 1 and CEA were
considered together and compared to EI&E histology, RT PCR was not sufficiently
sensitive to reliably detect metastatic disease in sentinel nodes in these breast cancer
patients. This was the case even when half the sentinel node was examined by RT PCR.
The technique is therefore not safe for use in clinical practice when applied to these three
markers. However CK 19 expression by the sentinel nodes from both groups of patients
was found to be significantly associated with NPI and therefore this marker would be
worthy of further study.
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Over the last 10 years sentinel node biopsy has emerged as an alternative to axillary
sampling or clearance for staging the axilla in breast cancer patients although clearly the
technique is still very much in its infancy. Many studies have now been published
achieving detection rates of over 90% and false negative rates of less than 5% and
negligible axillary recurrence rates have been seen in those studies where no other
axillary treatment has been given in the event of a negative sentinel node. The long term
follow up results of large multi centre phase III trials will not be available for some time
and there are many unanswered questions regarding the technique.
Perhaps the most controversial issues surrounding sentinel node biopsy are first how best
to analyse the sentinel node and second what size of sentinel node metastasis should be
regarded as clinically significant. Disease in the sentinel node detected by conventional
histology and techniques such as serial sectioning and immunohistochemistry are really
surrogates for macrometastases and micrometastases respectively. There is some
evidence that micrometastases are clinically significant although this point is
controversial.
Molecular techniques such as RT-PCR can identify isolated tumour cells. This technique
has been used particularly to look at bone marrow and blood samples from breast cancer
patients in order to identify metastases however relatively few studies have used the
technique to look at sentinel lymph nodes. As yet there has been no marker identified to
be 100% sensitive and 100% specific in the diagnosis ofmetastatic breast cancer. Three
of the most widely applied putative markers are cytokeratin 19 (CK 19), mucin 1 (MUC
1) and carcinoembryonic antigen (CEA). Both CK 19 and MUC 1 are expressed by at
least 90% of breast tumours while CEA is a less sensitive marker, expressed in around
70% of breast tumours. Due to the nature of the technique, any tissue evaluated in this
way is not available to the histopathologist and so an obvious dilemma is how much of
the sentinel node should be processed for RT PCR. There are as yet no published studies
using RT PCR to detect breast cancer markers in different amounts of sentinel lymph
node tissue.
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Based upon the available evidence to date the following hypotheses are proposed:
1. The expression of a panel of 3 breast cancer markers by sentinel lymph nodes
from breast cancer patients as determined by RT PCR will correlate more
accurately with histological findings than when expression of only a single
marker is considered.
2. The correlation between marker expression by RT PCR and conventional
histology will be higher when a greater proportion of the sentinel lymph node is
processed for RT PCR.
3. The number of histologically 'negative' sentinel nodes upstaged by RT PCR will
again be greater when a greater proportion of the sentinel nodes have been
examined by RT PCR.
The aims of this thesis were therefore to establish in sentinel nodes from breast cancer
patients:
1. The correlation between expression rates of CK 19, MUC 1 and CEA with each
other and with H&E histology
2. The expression rates of the three markers in half sentinel nodes (group 1) versus
4pm sections cut from sentinel nodes (group 2)
3. The percentage of histologically negative sentinel nodes upstaged by RT PCR for






Breast cancer is the most common cancer in women in the UK. It represents 30% of all
female cancers. Almost 41 000 women are diagnosed with the disease in the UK each
year and every month it accounts for over 1 000 deaths. On a positive note however,
deaths from breast cancer have reduced by over 20% in the past 10 years due to improved
adjuvant therapy together with screening and earlier presentation of symptomatic disease.
Current surgical management of breast cancer in most centres involves resection of the
primary tumour either by mastectomy or wide local excision together with axillary node
dissection. The past 100 years or so have seen many changes in surgical management
with a general trend towards less aggressive resection.
In 1907 Halsted published a report on radical mastectomy for the treatment of breast
cancer (Halsted, 1907). The next few decades saw more extensive procedures such as the
extended radical mastectomy and the super-radical mastectomy. A review published in
1932 however suggested that although these procedures usually resulted in adequate local
control, long term survival did not improve with more radical resections (Lewis et al.
1932). In 1948 Patey and Dyson described the modified radical mastectomy with
preservation of pectoralis major (Patey et al. 1948) and since then more conservative
procedures have in general prevailed.
The introduction of adjuvant radiotherapy to the breast and chest wall has also been a
significant factor in the move to less radical surgery, allowing conservation of the breast
where possible. Randomised trials beginning in the late 1960s demonstrated that the
combination of local surgery and radiotherapy could achieve results similar to those of
the radical and modified radical mastectomy (Veronesi et al. 1981, Fisher et al. 1985,
Fisher et al. 1989) and more recent trials such as the EORTC 10801 trial have confirmed
these results (Van Dougan et al. 1992).
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Experiments in the 1950s and 60s by Fisher showed that particles injected into breast
lymphatics rapidly appeared in the venous system, demonstrating venous-lymphatic
communications (Fisher et al. 1966) and therefore the possibility of blood-borne
metastases. His hypothesis suggested that the long term cure of breast cancer was
therefore dependent on systemic treatment as well as resection of the primary tumour.
Since then there have been many advances in adjuvant endocrine therapy and
chemotherapy with improved survival rates.
1.2. The lymphatic system in breast cancer
1.2.1. Basic anatomy of the lymphatic system
In the 17th century cadaveric and animal studies lead to the identification of the lymphatic
system and an atlas demonstrating the lymphatics of the entire human body was
published in 1787 by Paolo Mascagni. Lymphatic channels were later linked to regional
nodes.
The basic units of the lymphatic system are semi permeable lymph capillaries composed
of a single layer of endothelium and at this level the movement of cells and fluid is by
simple diffusion. These drain into one way collecting lymph vessels which travel
alongside veins to regional lymph nodes. Lymph trunks exit the nodes and drain into
terminal vessels. All organs apart from the central nervous system, spleen, liver lobules,
muscle and bone marrow contain lymphatics. There is communication between the
lymphatic and venous systems at the pre and post nodal level and so cells and antigens
can bypass regional nodes by this route.
1.2.2. The axilla and breast cancer
In 1849 Virchow postulated that lymph nodes were a physical barrier to the spread of
cancer (Virchow, 1849) and over the next few decades theories about cancer spread
18
developed (Stiles, 1892). These theories contributed to the evolving surgical
management of breast cancer such as Halsted's radical mastectomy in which the
ipsilateral axillary lymph nodes were excised en bloc (Halsted, 1907). This did not
however improve the survival rate compared to that ofhis predecessors who did not
perform axillary dissection. More radical lymphadenectomies have also been attempted
such as excision of the internal mammary and supraclavicular nodes but these did not
improve survival and were at the expense of significant morbidity (Urban et al. 1971).
An axillary dissection to some extent has however remained an integral part of the
surgical management of breast cancer over the past century.
Each quadrant of the breast is dominantly drained by 1 or 2 collecting lymphatic vessels.
The quadrants are also interconnected via the subareolar plexus as confirmed by one
recent cadaver study (Pavlista et al 2005). Within the axilla, 3 levels of lymph nodes are
recognised and are described according to their relation to pectoralis minor. Level I, II
and III nodes are situated lateral, posterior and medial to pectoralis minor respectively.
Disease spread within the axilla is usually sequential from level I through to III however
'skip metastases' occur when disease is found at a higher level but lower levels appear to
be disease free. Most of the studies which have looked at the pattern of axillary lymph
node metastases have found a skip metastases rate of less than 4% of all node positive
patients (Veronesi et al. 1971, Rosen et al. 1983, Van Lancker et al. 1995). Gaglia et al
however found skip metastases in 14.9% of 492 patients and they found that skip
metastases were more common when less than 4 nodes were tumour positive (Gaglia et
al. 1987).
As well as providing local control and removing tumour burden, axillary dissection
provides essential staging information. The overall incidence of nodal disease is 35-40%
and has remained unchanged over the last few decades. Lymph node status is the single
most important prognostic factor in breast cancer (Dent, 1996). The presence of axillary
node metastases decreases 5 year survival by 40% in patients with early breast cancer
(Nemoto et al. 1980, Carter et al. 1989). The number of involved nodes also has
prognostic significance (Nemoto et al 1980). Other important prognostic factors include
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the size of the primary tumour, grade, presence of lymphovascular invasion, oestrogen
receptor status and HER 2 status but none is as reliably correlated with outcome as
axillary node status. The Nottingham Prognostic Index (NPI) is an index derived from a
retrospective multivariate analysis based on lymph node stage, grade and tumour size
stratifying patients into 3 prognostic groups. It was first described in 1993 (Galea et al.
1993) and predicted 15 year survival rates for groups 1, 2 and 3 as 80%, 42% and 13%
respectively. Since then NPI has been widely applied and verified (Balslev et al. 1994,
D'Eredtia 2001) and in most centres patients now have their NPI calculated after surgery
and this is key in the decision making process regarding adjuvant therapy.
1.2.3. Diagnosis and prediction of axillary metastases
With accurate diagnosis of axillary disease being so important in the staging of breast
cancer and prediction of prognosis, reliable identification ofmetastases is vital.
Unfortunately clinical examination is very unreliable with approximately one third of
clinically 'node negative' patients having metastatic disease histologically and a similar
proportion of clinically 'node positive' having no disease histologically (Sacks et al.
1993). Other modalities shown to be inaccurate in staging the axilla include
computerised tomography (Isaacs et al. 1993), positron emission tomography (Nieweg et
al. 1993) and ultrasonography (Tate et al. 1989). More recently ultrasound has been used
to guide FNA or core biopsy of abnormal looking axillary nodes pre operatively. In one
study of 39 lymph node positive breast cancer patients, ultrasound guided core was found
to be 90% sensitive in the diagnosis ofmetastatic disease (Topal et al 2005). In another
recent study 92.8% of axillary nodes felt to be suspicious on ultrasound were found to
harbour metastases (Nori et al 2007). Studies looking at ultrasound-guided FNA have
reported much poorer sensitivities at around 55% (Kuenen-Boumeester et al 2003, Lemos
S et al 2005). If an ultrasound guided FNA or core biopsy identifies metastatic disease
preoperatively then these patients can be excluded from more selective axillary surgery
such as sentinel node biopsy.
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Many studies have looked at possible predictive factors for axillary metastases. In one
such study, tumour size and the presence of lymphovascular invasion were shown to
predict axillary involvement on multivanate analysis (Chadha et al. 1994). The incidence
of axillary disease in the literature varies from 0% (Mincey et al. 2001) to 12.2% (McGee
et al. 1996) for tumours of less than 5mm and from 11.3% (Mincey et al. 2001) to 23.2%
(McGee et al. 1996) fortumours of 6 to 10mm. Conversely, a large retrospective study
of over 1000 patients with T1 tumours (less than 10mm) showed that tumour size was not
a significant predictor ofaxillary node involvement (Anan et al. 2000). Another study
suggested that the size of the invasive component was a better predictor than total tumour
size for small cancers (Seidman et al. 1995) and so conflicting evidence may reflect
different sizing techniques. There may therefore be a role for selective axillary surgery
both for staging purposes as well as local control of disease in patients with small cancers
and given that patients are now presenting with smaller symptomatic cancers and screen-
detected cancers, a large number of patients could potentially avoid traditional axillary
treatment.
1.3. Management of the Axilla
A number of studies have looked at the incidence of axillary disease when the axilla is
left untreated. In one such study of over one hundred patients, tumours of less than
10mm had an axillary disease rate of only 10% at 10 years compared with 33% for
tumours larger than 21mm (Baxter et al. 1996). The NSABP-B04 trial randomised
patients to axillary surgery or no axillary surgery and found an overall axillary recurrence
rate of 21% in the untreated group (Fisher et al. 1985). This trial did not however
demonstrate a survival advantage in the axillary clearance group suggesting therefore that
axillary dissection was a diagnostic rather than a therapeutic procedure. In the NSABP-
B04 trial no adjuvant treatment was given and it may have had insufficient numbers to
exclude a small survival advantage. A meta-analysis (Orr, 1999) of almost 3000 patients
spanning over 4 decades from 6 randomised controlled trials showed an overall survival
advantage of 5.4% for axillary clearance. This meta-analysis however had a small
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proportion of T1 tumours and essentially no patients had adjuvant therapy and so the risk
reduction seen may be diminished by chemotherapy. Axillary recurrence is often
devastating when it occurs as it may take some time to become clinically apparent by
which time distant metastases are often present. The disease within the axilla itselfmay
produce physical symptoms such as pain and lymphoedema and there are also significant
psychological implications.
A recent survey, completed by 371 breast surgeons, of the surgical management of the
axilla in the UK was published recently (Gaston et al. 2004). 40% of the surgeons used
both axillary dissection and sampling; 28% used axillary dissection alone; 17% used
axillary dissection, sampling and sentinel node biopsy; 10% used axillary dissection and
sentinel node biopsy and 5% used sampling alone. Of those performing axillary
dissection, 49% perfonned a level III clearance; 42% level II and 9% level I. Of the
surgeons performing sentinel node biopsy, 52% were using the technique within a trial
setting only and 36% outwith trials only.
1.3.1. Axillary dissection
Axillary dissection or clearance remains the most common means ofmanaging the axilla,
in terms of providing staging information and providing local control, in breast cancer
patients. A complete (level III) axillary clearance includes the nodes from levels I to III.
In the UK level III and level II (levels I and II) axillary clearances are performed in
approximately equal numbers (49% versus 42%) with very few surgeons clearing only
level I nodes (9%) (Gaston et al. 2004). The decision to perform a level II or III
clearance presumably comes down to the surgeons individual preference in most cases
and in some cases will be dictated by the presence of abnormal nodes at operation. The
surgical boundaries of a level II clearance are the axillary vein superiorly, latissimus dorsi
laterally and the medial border of pectoralis minor medially. In a level III clearance
nodes medial to pectoralis minor arc also excised.
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1.3.2. Axillary sampling
Axillaiy clearance is associated with significant side effects which will be discussed
below. Different techniques have therefore been developed in an attempt to accurately
stage the axilla without carrying out such an extensive lymphadenectomy. Axillary node
sampling was initially introduced as a means of defining patients in whom postoperative
radical radiotherapy, including axillary irradiation, could be avoided after simple
mastectomy. Reports using axillary sampling as an alternative to clearance started to
appear in the literature in the early 1980s. Randomised trials comparing 3 or 4 node
sample with axillary clearance in Cardiff and Edinburgh showed no significant difference
in the node positivity between the 2 groups and equal survival rates (Chan et al. 1993,
Steele et al 1985). A large study advocating the use ofaxillary sampling carried out a
retrospective review of 499 axillary dissection specimens and showed that assessment of
3 to 6 of the largest and firmest lymph nodes in the specimen lead to detection of 93-98%
of the node positive patients (Cserni, 1999). Murray et al reviewed 26 patients who had
developed axillary recurrences after a 'negative' 4 node axillary sample and found that
with serial sectioning and immunohistochemistry, 8% had micrometastases. This was
however not statistically different from a control group who had not developed
recurrences. This suggested that the recurrences were not due to missed axillary
metastases in the sample group.
Some studies however suggest increased axillary recurrence rates (Graverson et al. 1988),
and poorer overall survival (Axelsson et al. 1992) when fewer nodes were excised. One
study of 960 consecutive patients (Mathieson et al. 1990) showed that the probability of
finding at least one positive node increased continuously for up to 10 nodes removed and
then levelled off after 10 nodes had been excised at 64% overall node positivity. The
authors therefore suggested that at least 10 lymph nodes should be excised to minimise
understaging the axilla. This idea has been corroborated by a more recent study in which
over 31 000 breast cancer operations were reviewed and in this the node positivity rate
was found to increase the more nodes were retrieved. Harvesting over 20 nodes
compared to between 10 and 14 nodes increased the node positive rate from 14.2% to
25.9% for tumours up to 5mm in diameter (Axelsson et al 2007).
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1.3.3. Axillary radiotherapy
Axillary radiotherapy offers an alternative to surgery in terms of providing locoregional
control, however it has no role in staging. In the 1970s there was a trend for simple
mastectomy (without axillary dissection) with postoperative radical radiotherapy
including axillary irradiation. Currently radiotherapy is most often used to treat the axilla
in combination with axillary sampling where the sample reveals positive nodes. In an
Edinburgh study patients were randomised to 4 node axillary sampling with subsequent
axillary radiotherapy if nodes were involved or a level II axillary clearance with no
difference in axillary recurrences between the 2 groups (Forrest et al. 1995). A more
extensive randomised study from the same institution has shown similar results as well as
reduced morbidity in the sample +/- radiotherapy group (Chetty, 2001).
1.3.4. Sentinel lymph node biopsy
Excision of the first draining 'sentinel' node, which will be discussed in detail below, has
been used increasingly to stage the axilla over the past 10 years. It involves lymphatic
mapping and therefore selects the lymph node or nodes which are, anatomically, most
likely to harbour metastases.
1.4. Morbidity of axillary treatment
The most important cause ofmorbidity after axillary surgery or radiotherapy is
lymphoedema of the corresponding arm. Lymphoedema is usually measured subjectively
and therefore often goes unreported. In addition it can take time to develop with the
mean time from surgery to onset of lymphoedema being 14 months in one study (Werner
et al. 1991). The incidence is similar for both surgery and radiotherapy to the axilla but
with surgery the incidence increases the more extensive a dissection is performed
(MacKaren et al. 1992). In most studies, surgery and radiotherapy combined produce the
highest rates of lymphoedema (Aitken et al. 1989). An extremely rare complication of
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lymphoedema is the development of lymphangiosarcoma, Stewart-Treves syndrome
(Stewart, Treves. 1948).
Up to a third of patients experience chronic pain after a level III clearance (Ivens et al.
1992). Brachial plexopathy occurs in 5% of patients at between 10 months and 4 years
post radiotherapy and results in constant pain and weakness of the arm (Spittle, 1995).
Paraesthesia of the shoulder and upper arm resulting from division of the
intercostobrachial nerve occurs in 70-80% undergoing a level II axillary clearance (Lin et
al. 1993). Preservation of the nerve results in chronic pain in about a third ofpatients.
Seromas occur in up to 50% of patients undergoing axillary dissection despite the use of
suction drains (Tadych et al. 1987). Postoperative haematomas, wound infections and
delayed wound healing are also sources ofmorbidity.
1.5. Sentinel lymph node biopsy
During the 1950s and 60s various lymphatic mapping studies were reported, including
injection of blue dye into the testicle with identification ofblue lymphatic channels in the
groin (Busch et al. 1963). Several years later breast lymphatics and a blue draining
axillary node were imaged using blue dye (Kell et al. 1970). In 1977 the urologist
Ramon Cabanas injected blue dye into a squamous carcinoma of the penis and then
observed a blue lymph node in the groin (Cabanas, 1977). He described this node as the
'sentinel node', arguing that this was the first node to drain the cancer and that if this
node was disease-free then lymphadenectomy was unnecessary. This concept revived
Halsted's concept of sequential lymphatic drainage. Around the same time a group from
UCLA working on melanoma proposed that lymphatic drainage varied between patients
and therefore an intraoperative technique was required to identify each individual's
drainage pattern. In this study, initially presented to the WHO in 1989 (Morton et al.
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1989) and then published in 1992 (Morton et al. 1992), they carried out lymphatic
mapping by injecting blue dye intra-dermally around the primary melanoma in 223
consecutive patients.
Sentinel node biopsy, where lymphatics are traced by some means to one or a few
draining sentinel nodes, developed during the early 1990s. Most early reports used the
technique in melanoma patients and then increasingly studies emerged using it in the
management of breast cancer.
1.5.1. False negative rate
For sentinel node biopsy to be a useful clinical tool it must accurately predict the
presence of lymph node metastases. Patients in whom the sentinel node is negative but
other draining nodes in tire lymphadenectomy specimen are positive are termed 'false
negatives'. In breast cancer patients, the false negative rate can only be calculated when
sentinel node biopsy is performed in conjunction with an axillary clearance. It is
calculated as a percentage of the total number of positive patients (true positives plus
false negatives). The false negative rate therefore determines the number of patients who
would be incorrectly staged using sentinel node biopsy. Such patients would potentially
miss out on adjuvant therapy and therefore have a poorer outcome.
1.5.2. Identification techniques
In Morton's study ofmelanoma patients (Morton et al. 1992), lymphatic mapping was
carried out using isosulphan dye injected around the primary tumour and then blue
stained lymphatic channels were traced to the blue sentinel node. They identified at least
one blue node in 82% of cases and identified a clear learning curve for the procedure
where more experienced surgeons obtained better detection rates. The following year
studies were published using injected technetium labelled colloid and a gamma probe to
identify radioactive sentinel nodes both in melanoma (Alex et al. 1993) and breast cancer
(Krag et al. 1993) patients. A combination of blue dye and radiolabelled colloid was then
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used both in melanoma (Albertini et al. 1996) and breast cancer (Hill, 1999) with
improved detection rates. Blue dye and radioactive colloid do not always identify the
same node(s) and so the two methods complement each other. The American College of
Surgeons Oncology Group trial ACOSOG ZOO 10 (White et al. 2004) which is a phase III
trial not yet reported, has shown incidentally that in over 5000 women who underwent
sentinel node biopsy using different detection techniques, identification of the sentinel
node was similar for dye alone, colloid alone or the combined method. Most centres
performing sentinel node biopsy now use the combined approach to improve detection
rates and also reduce false negative rates. This obviously depends on having access to
nuclear medicine and it is probably more important to have performed a standard
technique many times than to always use dye and colloid together. Any node which is
blue, or with blue lymphatic channels leading up to it, or radioactive ('hot') or blue and
hot is identified as a sentinel node. A 'hot' node has been defined by most studies as a
node with a count rate of greater than or equal to 10 times the background radioactivity
rate (Cox et al 1998, Bass et al 1999, Sato et al 2002). In cases where more than one hot
sentinel node are retrieved, the hottest node is not always the pathologically positive node
as shown by one study where in 27.5% of 40 cases examined this was the case. However
when the hottest sentinel node retrieved was used as a reference point and 10% of this
activity used as the cut off for identifying a node as a sentinel node, the technique was
97.5% sensitive in predicting overall axillary node status (Bourgeois et al 2003).
Two types of blue dye have been used in sentinel node biopsy, isosulphan blue and patent
blue, and these are biochemically similar. They bind to albumin and then are selectively
taken up by lymphatics and excreted into bile (90%) and urine (10%). There is minimal
diffusion into the surrounding soft tissues unlike other dyes such as methylene blue.
In Europe the radioactive colloid used most in sentinel node biopsy is a nanocolloid
labelled with technetium 99 which has a particle size of 80nm. In the USA a sulphur
colloid, particle size 200nm, is used. The smaller particles of the colloid used in Europe
are more rapidly absorbed and so appear in the draining lymph nodes faster. These
colloids will accumulate in lymph nodes regardless ofwhether they contain metastases
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and in fact heavily involved lymph nodes often have reduced tracer uptake due to
blockage of afferent lymphatic channels by tumour deposits. The dose injected varies in
the literature from 7MBq (Veronesi et al. 1997) to 370MBq (Van der Ent et al. 1993).
Radioactive nodes can be identified preoperatively using a gamma camera and the site of
hot spots marked on the patients skin, and intraoperatively using a hand held gamma
probe. The optimum timing of tracer injection and preoperative imaging is debatable
and different reports suggest obtaining static images between 2 hours (Borgstein et al.
1998) and 6 hours (Roumen et al. 1997) post injection. The gamma probe detects gamma
photons generating an audible output which is then displayed as a 10 second count to
quantify the level of radioactivity. The radioactivity of a sentinel node depends on the
size of the node and the number of associated afferent lymphatic channels as well as its
position in the drainage order. In one study the positive node was the hottest in only 60%
of patients in whom more than one sentinel node was identified (Eubus et al. 1999). The
probe can be used either with the skin intact or after incision and usually a combination
of both is used to identify any hot nodes. The probe is useful after harvesting of the
sentinel node to detect any residual radioactivity in the axilla and therefore any additional
sentinel nodes.
There has been much debate as to the best injection technique both for blue dye and
radioactive colloid. Initially, subdermal and peritumour injection routes were used.
Within the breast there is a higher concentration of lymphatics subdermally and so
injection under the skin which overlies the tumour results in more rapid uptake of tracer.
However it is argued that injection around the tumour itself is more accurate in
determining the individual lymphatic drainage pattern. The precise communication
between breast and overlying dermal lymphatics is unknown however one study showed
complete concordance between the sentinel node of a breast tumour and the overlying
skin in 33 patients by using subdermal blue dye and peritumoural radioactive colloid
(Borgstein et al. 1997).
An injection technique which has emerged since the sentinel node biopsies were
performed in the current study is the subareolar injection route. Tire first study to look at
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this route was published in 1999 and out of 40 cases the detection rate was 98% and the
sensitivity for detection of axillary disease was 100% (Kern 1999). Subsequent studies
confirming that this technique produced detection rates and false negative rates
equivalent to or better than peritumoural injection emerged a few years later (Peley et al
2004, Chagpar et al 2004). One main advantage of this technique is in the management
of patients with multifocal breast cancer. In one study of 40 patients with multifocal
disease subareolar radioactive colloid was injected and both the detection rate and
sensitivity were 100% (Layeeque et al 2003). Two studies have also been published
looking at intraoperative subareolar injection of radioisotope. The mean delay between
injection of radioisotope and axillary incision was between 15 and 20 minutes and
detection rates greater than 95% were achieved in both (Layeeque et al 2004, Zogakis et
al 2005).
1.6. Sentinel Lymph Node Biopsy in Breast Cancer
Since the mid 1990s there have been many studies published looking at sentinel node
biopsy in breast cancer and in many centres it has now replaced traditional axillary
dissection, although still largely on a trial basis. Uptake of the technique in the UK has
been slower and it is not yet the standard of care in most UK centres. The Royal College
of Surgeons of England is currently mnning a training programme for sentinel node
biopsy ('New Start'). This involves a theory day at a regional centre, which should be
attended by as many members of the multidisciplinary breast care team as possible, and
then a training day at the trainee team's hospital where 5 sentinel node biopsies are
guided by an experienced sentinel node surgeon. An audit phase is then completed in the
local hospital with a further 30 cases performed by the same surgeon during which time a
satisfactory detection rate and false negative rate should be achieved.
In many patients more than one sentinel node is identified in the axilla. The average
numbers of sentinel nodes harvested per patient in a selection ofpublications available at
the start of this study are detailed in table 1:
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no. patients average no SLN/patient reference
57 2.2 Albertini '96
160 1.4 Veronesi '96
440 1.9 Cox '98
405 2.6 Krag '98
110 1.8 Morrow '99
458 2.1 Hill '99
132 2.1 Giuliano '00
69 2.0 Fissell '01
Table 1: Average number of sentinel nodes found per patient in published series
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1.6.1. Initial studies determining accuracy
The initial studies published of sentinel node biopsy in breast cancer concentrated on
determining the detection rate, sensitivity and false negative rate and therefore the overall
safety of the technique. In these studies a completion axillary dissection was performed
following detection of the sentinel node. Table 1 displays a selection of these studies
from the literature. Analysis of the sentinel node varied from standard H&E histology (*)
to serial sectioning (n) and immunohistochemistry (°).
author/year no. patients technique DR FNR
Giuliano'94* 174 dye 65.5% 11.9%
Albertini'97* 62 dye+colloid 92% 0
Veronesi'97a° 163 colloid 98% 4.7%
Cox'98o° 466 dye+colloid 94.4% 0.9%
Krag'98* 443 colloid 91.4% 11.4%
Roller'98* 98 dye 97.9% 5.9%
Frisell'Ol* 75 dye+colloid 92% 11.1%
Tafra'Ola0 535 dye+colloid 87.1% 12.8%
Smillie'Oln0 106 dye+colloid 83.9% 5.5%
Table 2: Sentinel node biopsy studies where completion axillary dissection was
performed
DR: detection rate
FNR: false negative rate
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1.6.2. Studies without axillary dissection
There are now a number of studies where patients with a negative sentinel node have not
had any further axillary surgery or treatment. No long term follow up data regarding
axillary recurrence is yet available but, given that the mean time to axillary recurrence is
18 months, the short and medium term follow up data of these studies look very
promising. In table 2 the number of patients detailed in each study refers to the number
of sentinel node negative patients who did not have an axillary dissection.
author/year No. patients MFU ARR
Schrenk'01 227 22 months 0
Roumen'01 100 24 months 0
Takei'02 358 21 months 0
Reitsamer'04 200 36 months 0
Torrenga'04 104 57 months 0.96%
Veronesi'05 953 38 months 0.31%
Zavagno'05 479 36 months 0
Haid'06 180 47 months 0.56%
Takei'07 822 34 months 1.4%
Table 3: Sentinel node negative studies where no axillary dissection was performed
MFU: mean follow up
ARR: axillary recurrence rate
There were no incidences of distant metastases other than 3 cases (2.9%) in the study by
Torrenga et al.
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A few studies have recently been published showing medium-term survival data for
patients who have undergone sentinel node biopsy alone. At the end of 2006 Veronesi et
al published their updated survival data with a median follow up of 79 months (Veronesi
et al 2006). This study of over 500 patients reported 5 year survival rates of 96.4% and
98.4% in patients who had undergone axillary clearance and sentinel node biopsy alone
respectively. A recent Japanese study of over 1300 patients randomised to sentinel node
biopsy alone versus axillary clearance with a median follow up of 31 months has found
that the type of axillary surgery has no impact on disease free survival or overall survival
(Takei et al 2006).
1.6.3. Trials
There are now several large multi-centre randomised controlled trials underway to assess
both the long term safety of the technique and also the reduction in morbidity over
conventional axillary treatment.
Within the UK, the ALMANAC trial (Clarke et al. 2001) began in 2001 with an initial
audit phase where individual surgeons have to perform 40 sentinel node biopsies and
achieve an overall detection rate of 90% and false negative rate of less than 5% before
entering the randomised phase comparing sentinel node biopsy where the node was
negative versus axillary clearance or 4 node sample. Primary end points include axillary
morbidity and quality of life as well as economic issues. Of the first 13 surgeons to
complete phase I, all achieved the necessary detection and false negative rates to proceed
to phase II (Clarke et al. 2004). Data from the first 1031 patients randomised to sentinel
node biopsy alone or axillary clearance/sample has now been published and this shows
overall quality of life and arm functioning scores better in the sentinel node biopsy group.
In addition there was no increase in anxiety in the group of patients undergoing sentinel
node biopsy and there were fewer drains used, shorter hospital stay and reduced time to
return to normal activities in this group (Mansel et al 2006).
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In the USA the NSABP-B32 trial (Krag et al. 2004) is a phase III multicentre randomised
trial comparing sentinel node biopsy with axillary dissection. 217 surgeons from 73
institutions arc currently accruing patients who are randomised to level II axillary
dissection or sentinel node biopsy with completion axillary dissection only in patients
with an H&E positive sentinel node. The primary aim is to determine whether sentinel
node biopsy alone provides a similar survival rate and regional control as axillary
dissection but with fewer side effects. The secondary aim is to look at the effect of
'occult' metastases within the sentinel node on survival. In the ACOSOG ZOO 10 trial
(White et al. 2004), which has now closed, patients underwent bone marrow biopsy just
prior to sentinel node biopsy. IHC was then performed on the bone marrow and sentinel
node to determine prognostic accuracy. The results of this trial are awaited.
Another large randomised multicentre phase III trial comparing sentinel node biopsy to
axillary dissection is the Royal Australian College of Surgeons's SNAC trial. By 2004
789 out of the target 1000 patients had been recruited (Gill et al. 2004).
1.7. Pathological analysis of sentinel lymph nodes
1.7.1. Paraffin histology
When an axillary clearance is performed, it is unlikely that all axillary nodes are
examined histologically or otherwise. Firstly some nodes may be left behind by the
surgeon and secondly some small nodes may be missed by the pathologist when the
specimen is cleared. Nodes that are retrieved usually undergo a limited examination as
analysis ofmultiple sections by histology and immunohistochemistry (IHC) is not
practical. Sentinel node biopsy presents the pathologist with just one or a few nodes
rather than 20 or more and so a more detailed analysis of this node is practical.
Analysis of lymph nodes at multiple levels by haematoxylin and eosin (H&E) increases
the detection ofmetastases (Ludwig Group 1990, Pickren 1961, Fisher et al. 1978,
Wilkinson et al. 1982). IHC also increases the diagnostic yield and upstages nodes that
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are negative by conventional histology (Hainsworth et al. 1993, Byrne et al. 1987, Wells
et al. 1984). These techniques allow the detection of smaller metastatic deposits.
Micrometastases, defined as deposits smaller than 2mm, and isolated tumour cells can be
identified using more sensitive techniques. The clinical significance of such metastases
will be discussed below.
At present the optimum pathological handling of sentinel nodes has not been established
and there is currently wide variation in practice between different centres. A recently
published study (Csemi et al. 2004) in which questionnaires were completed by nearly
400 European pathology units suggested that 70% used IHC routinely if initial H&E
histology was negative and 60% performed intra-operative analysis of the sentinel node.
Only 4% of units were using molecular staging. Another recent study performed
extensive analysis of 173 sentinel nodes, examining each node at 10 levels by H&E and
IHC and found that with the addition of 2 additional H&E levels and 1 IHC level (where
the initial H&E at one level was negative) correctly identified the sentinel node status in
97.9% of patients (Yared et al. 2002).
Many of the published series of sentinel node biopsy in breast cancer have used serial
sectioning and IHC where initial H&E histology was negative (see table 2). The studies
detailed in table 4 are examples of those that have looked specifically at the ability of
serial sectioning and IHC to upstage sentinel nodes. The upstaged rates given are the
result of serial sectioning and IHC combined and are expressed as a proportion of the
total number of patients.
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Author/year no. patients %upstaged





Table 4: Use of serial sectioning and IHC to upstage sentinel nodes in breast cancer
1.7.2. Intra-operative analysis
Intra-operative analysis of the sentinel node allows a completion axillary clearance to be
performed at the time of initial surgery if the sentinel node is found to be positive. This
therefore spares a significant number of patients a second procedure. The reliability of
intra-operative analysis depends on the tumour load as well as the size of the node itself.
Clearly the more sections are examined, the higher the tumour pick up rate will be.
However the examination must be performed fast enough for it to be acted upon in
theatre and so a balance must be struck between the number of sections examined and the
time and cost involved.
1.7.2.1. Frozen section
A single frozen section can usually be prepared and examined within 30 minutes. Table
5 displays a selection of studies that have examined the accuracy of frozen section
analysis of sentinel nodes in breast cancer. There was one false positive in the study by
Tanis et al giving a specificity of 99% but in the other 4 studies the technique was 100%
specific.
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Table 5: Accuracy of frozen section analysis of sentinel nodes in breast cancer
1.7.2.2. Imprint cytology
Imprint cytology is a faster technique than frozen section but very few cells are
examined. In a meta-analysis of 31 studies of imprint cytology of sentinel lymph nodes
the overall sensitivity was 63% and specificity 99% (Tew et al. 2005).
1.8. Reverse transcription polymerase chain reaction (RT PCR) and breast cancer
RT PCR is a very sensitive technique which detects and amplifies mRNA. It can detect
an isolated tumour cell among one million normal cells. RT PCR has been used to detect
different breast and other cancermarkers in blood, bone marrow and lymph nodes in an
attempt to identify occult metastases. Many breast cancer markers have been studied
however tumours display heterogeneous gene expression and so a single mRNA marker
may be inadequate for the reliable detection ofmetastases. In one study which used RT
PCR to identify 5 potential breast cancer markers in healthy donor blood, normal lymph
nodes and sentinel nodes from breast cancer patients, variable expression was found in
the blood and normal nodes (Bostick et al. 1998). There was no single marker which was
consistently expressed by histologically positive nodes however combining the results of
all 5 markers, 90% of the histologically positive nodes displayed expression of at least
one marker. Another study looking at expression ofmultiple markers by sentinel nodes
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found that none of the markers individually had a sensitivity ofmore than 77.8% but
using the results of expression ofall 5 markers, the sensitivity was 95.6% (Manzotti et al.
2001). A 2 marker protocol has been suggested by one group who found that the
combination of any 2 of the markers they studied gave optimum results and the addition
of a third marker to the panel did not improve metastastic detection rates (Fabisiewicz et
al 2004). The false negative rate ofRT PCR may at least in part be explained by
sampling error because, by the nature of the process ofRT PCR, the part of the node
examined by this technique is not examined histologically and vice versa.
The first report to show that over expression of breast cancer associated genes in patients
with histologically node negative breast cancer was correlated with traditional prognostic
indicators was published recently (Gillanders et al. 2004). This study used RT PCR to
detect 7 different breast cancer markers in 489 patients and found that 33% of
histologically negative lymph nodes were RT PCR positive and that RT PCR positivity
was significantly associated with prognostic factors such as grade.
Tire RT PCR results obtained in this study were qualitative however since the laboratory
work was carried out real time quantitative PCR has emerged as a technique for
examining sentinel nodes. In one recent study this was found to be a more sensitive
technique in the diagnosis of metastatic disease than qualitative PCR (Dell "Orto et al
2006).
1.8.1. Putative breast cancer markers
In the present study the following three breast cancer markers have been selected:
cytokcratin 19 (CK 19), mucin 1 (MUC 1) and carcinoembryonic antigen (CEA). The
evidence for each of these markers will be discussed in detail below but in general the
literature suggests that at least 90% of breast cancers express CK 19 and 100% express
MUC 1. The reported expression of CEA is more variable with most studies suggesting
that approximately 70% of cancers are CEA positive. The specificity of the three
markers is even less easy to establish and expression of all three has been reported in
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control blood samples and lymph nodes. Other studies however report negative
expression in controls.
CK 19 MUC 1 CEA
sensitivity >90% 100% approx 70%
specificity ? ? ?
Table 6: Sensitivity and specificity of CK 19, MUC 1 and CEA as breast cancer
markers
1.8.1.1. Cytokeratin 19
Cytokeratin 19 belongs to a family of intermediate filament proteins expressed by
epithelial cells (Moll et al. 1982). Malignant cells generally retain the intermediate
filaments of their progenitor cell types and so cytokeratins are used to characterise
neoplastic cells of epithelial origin.
Many studies have used immunohistochemistry to verify cytokeratin expression by breast
tissue. Bartek used mononclonal antibodies to 2 different epitopes of CK 19 and found
that while in benign breast lesions there was heterogeneous expression with up to 50% of
the cells remaining unstained, there was homogeneous positive staining in all invasive
breast cancers (Bartek et al. 1985). A later study looking at the expression of different
cytokeratins using a panel ofmonoclonal antibodies in benign and malignant breast
lesions found that cytokeratin 19 was expressed by all lesions. The expression of some
other cytokeratins was more variable (Heatley et al. 1995).
Immunohistochemistry has also been employed to identify CK 19 expression in the
axillary nodes, bone marrow or peripheral blood of breast cancer patients. In one study
of 358 axillary lymph nodes from breast cancer patients, 5.9% were found to express CK
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19 and this compared to 4.5% found to harbour metastases by H&E histology (Inokuchi
et al. 2003).
More recently RT PCR has been used in breast cancer patients to determine CK 19
expression. In one study CK 19 expression was found in all of 23 primary breast cancers
examined (Noguchi et al, 1996). The expression level of CK 19 mRNA was however
found to be variable, although always present to some extent, in a quantitative RT PCR
assay looking at 52 primary tumours (Schroder et al. 2003). The sensitivity of CK 19
expression, as determined by RT PCR has not been corroborated by all studies such as
that by Papadimitriou which found that 10% of invasive cancers did not express CK 19
(Papadimitriou et al. 1993). Low expression rates have also been found in vitro by the
breast cancer cell line MCF 7 (Eltahir et al. 1998).
Inokuchi found that 13.1% of 358 axillary lymph nodes displayed CK 19 expression
compared to an H&E positivity rate of 4.5% (Inokuchi et al. 2003). Zhang used RT PCR
to analyse axillary drainage fluid and found that CK 19 expression was an independent
predictor of locoregional recurrence (Zhang et al. 2006). Many papers have reported the
CK 19 expression of peripheral blood in breast cancer patients such as that by Xenidis
which reported CK 19 expression in 21.6% of 167 node negative breast cancer patients
and in addition these patients had a significantly increased risk of early relapse or disease
related death (Xenedis et al. 2006). The detection of CK 19 in peripheral blood has also
been used to monitor response to neoadjuvant chemotherapy and in one study of 53
patients there was a significant reduction in CK 19 expression after chemotherapy
(Manhani et al. 2001).
Variable specificity rates for CK 19 expression have been found in the literature. In one
study where peripheral blood from 30 healthy controls and from 15 patients having
benign breast biopsies were subjected to RT PCR, no expression of CK 19 was found
(Kahn et al. 2000). Datta found similar results with only one of 39 controls displaying
CK 19 expression in peripheral blood and the single positive was a patient with chronic
myelogenous leukaemia (Datta et al. 1994). However two studies have each shown CK
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19 expression in around one fifth of control blood samples (Wong et al. 2001, Krismann
etal. 1995).
Few studies have included normal lymph nodes in their evaluation of CK 19 expression
by RT PCR and they have looked at only a few nodes each. The absence of CK 19
expression by normal lymph nodes was found by some studies (Traweek et al. 1993,
Noguchi et al. 1996) but in another a few normal nodes did express CK 19 (Bostick et al,
1998).
1.8.1.2. Mucin 1
Mucin 1 (MUC 1) is a transmembrane high molecular weight glycoprotein which is
important for cell adhesion. It is also known as CA 15.3 and PEM (polymorphic
epithelial mucin) and is uniformly and highly expressed by primary breast tumours. The
overexpression seen in breast cancer cells results in reduced cell to cell and cell to
extracellular matrix adhesion and therefore allows cell detachment. Overexpression of
MUC 1 has also been found to induce T cell apoptosis (Gimmi et al. 1996).
Since the 1980s many authors have used monoclonal antibodies to detect MUC 1 in the
serum of breast cancer patients. In a large retrospective multicentre study of 500 patients
over a 7 year period, the preoperative serum MUC 1 level was found to correlate with
stage, tumour size, lymph node status and the presence ofmetastases (O'Hanlon et al.
1995). MUC 1 level was not however found to be an independent prognostic factor in
this study. Elevated levels ofMUC 1 were found in the peripheral blood in 68.4% of 98
patients with advanced or recurrent breast cancer (Iwase et al. 1995). Another study of
252 patients found a significant correlation between elevated serum MUC 1 and
locoregional recurrence and time to development ofmetastatic disease, with a mean lead
time of 9.9 months between elevation of MUC 1 and diagnosis ofmetastases (Coveney et
al. 1995). Pectasides found that monitoring serum MUC 1 was 68.2% sensitive in
detecting disease progression in a study of 209 patients (Pectasides et al. 1996). A study
with longer follow up data of 5 years or more in 103 patients found that MUC 1 levels
41
were 61.1% sensitive and 91.2% specific for detecting cancer recurrence (Lumanchi et al.
1999).
Serum MUC 1 levels have been used less successfully to monitor response to breast
cancer therapy. In one study of 99 breast cancer patients undergoing neoadjuvant
chemotherapy the MUC 1 serum level did not change after chemotherapy even when
there was a good clinical response however an elevated pre-treatment level was
associated with an increased recurrence rate (Bottini et al. 1997).
Breast cancermucin has a novel carbohydrate epitope and is therefore antigenically
distinct from normal breast tissue mucin. The heavily sialylated side chain of breast
cancer MUC 1 has greater immunogenicity and the monoclonal antibodies that have been
developed have been considered in the development of anticancer vaccines as well as
being used to detect semm MUC 1 as described above. A live recombinant vaccinia
virus coexpressing human MUC 1 and the human cytokine IL 2 was used in 9 breast
cancer patients in whom there were increased numbers of T memory cells and no adverse
reactions (Scholl et al. 2000).
Identification ofMUC 1 mRNA by RT PCR has been carried out in primary tumours,
axillary nodes, peripheral blood and bone marrow. In one study 10 out of 10
histologically positive axillary nodes also expressed MUC 1 and 6% of 53 histologically
negative nodes were upstaged (Noguchi et al. 1996). The presence ofMUC 1 in
peripheral blood was found in 24% of patients with operable breast cancer compared to
45% of patients with advanced disease in another study of 122 patients (deCremoux et al.
2000).
Some studies have suggested that MUC 1 is a specific breast cancer marker which is
rarely expressed by non epithelial tissues (Zotter et al. 1988, Noguchi et al. 1994). It has
however been detected in peripheral blood and lymph nodes from healthy controls
(Bostick et al. 1998).
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1.8.1.3. Carcinoembryonic antigen
Carcinoembryonic antigen (CEA) is a tumour antigen associated with poorly
differentiated tumour cells. Initial publications suggesting that serum CEA could be used
as a breast cancer marker appeared in the mid 1970s. Many studies then assessed serial
CEA evaluation as a means ofmonitoring the disease. Some found that elevated CEA
was correlated with subsequent progression and that the rise in levels were seen several
months before relapse was clinically apparent (Lokich et al. 1978, Myers et al. 1978).
Similar results were found in a more recent study of 135 patients in which a rise in serum
CEA was found on average 7 months before relapse was clinically apparent (Jezersek et
al. 1996).
As well as being used to monitor disease progression, CEA has been found to be an
independent prognostic factor in breast cancer by some studies (Mansour et al. 1983,
Ebeling et al. 1999). The study by Ebeling of 550 patients without metastatic disease at
diagnosis found that the preoperative CEA level was an independent prognostic factor for
overall survival on multivariate analysis. In a recent study of 103 patients with locally
advanced breast cancer undergoing neoadjuvant chemotherapy, serum CEA was found to
be an independent predictor of outcome (Martinez-Trufero et al. 2005). Serum CEA has
also been shown to be significantly correlated with the size of the primary tumour and
also axillary node status (Lumanchi et al. 2000).
CEA is not however universally expressed by breast cancer cells. Overall expression
rates by primary tumours of 65% and 75% were found in two different studies (Halter et
al. 1984, Marchetti et al. 2001). Not surprisingly other studies have failed to verify CEA
as an accurate predictor of progression such as one large study of 664 breast cancer
patients where serial CEA had a diagnostic accuracy of 83% for relapse and a positive
predictive value of only 27% (Sutterlin et al. 1999). The sensitivity of serum CEA was
only 27% for detection of visceral metastases and 46% for detection of bony metastases
in another study ofover 1000 patients (Given et al. 2000). Elevation of CEA occurred in
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only 38% of 549 patients with recurrent disease in a study with at least 5 years follow up
(Guadagni et al. 2001).
1.8.2. RT PCR analysis of sentinel lymph nodes
RT PCR has been used to evaluate sentinel lymph nodes from breast cancer patients in
several studies and a few examples are listed in table 7 below. There are also now some
reports of using real time RT PCR to analyse sentinel lymph nodes (Schroder et al. 2003)
Despite relatively few studies there are now commercially available RT PCR kits which
are being targeted at the analysis of sentinel lymph nodes.
author/year no. patients markers(s) % upstaged
Peley'01 68 CK20 20.6%
Branagan'02 50 Mammoglobin 8%
Sakaguchi'03 108 CK19/EGP2 16%
Weigelt'04 70 nodes CK19/p 1B/EGP2/SBEM 10%
Table 7: Studies using RT PCR to analyse sentinel lymph nodes in breast cancer
1.9. Axillary micrometastases
A micrometastasis is usually defined as a metastatic deposit with a maximum diameter of
less than 2mm. Very small metastases are now also referred to as isolated tumour cells
(ITC).
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1.9.1. Impact of axillary micrometastases on survival
Initial studies published in the 1960s and 70s suggested that 'occult' axillary node
metastases or micrometastases detected by serial sectioning or IHC did not influence
survival (Pickren et al. 1961, Fisher et al. 1978, Huvos et al. 1971, Attiyeh et al. 1977).
An important study which found that micrometastases did reduce survival was that
published by the Ludwig group in 1990. It found that micrometastases were present in
9% of 921 patients using serial sectioning and IHC and found that these patients had a
16% reduction in disease free survival. Other studies which have also found a reduction
in survival associated with axillary micrometastases are summarised in table 8.
author/year no. patients incidence MM DFS reduction
Trojani'87 162 14% 22%
Sedmark'89 45 11% 11%
Ludwig Gp'90 921 9% 16%
Chen'91 80 29% 16%
deMascarel'92 218 23% 10%
Hainsworth'93 343 12% 15%
Table 8: Studies showing reduced survival associated with axillary micrometastases
MM: micrometastases
DFS: disease free survival
Some studies have looked at whether sentinel node micrometastases can predict the
presence ofmetastatic disease elsewhere in the axilla. Of these, some have shown that
they do predict other disease (Viale et al. 2001, Schrenk et al 2005) and others have
shown no correlation (Foumier et al. 2004, Rutledge et al. 2005). Those that show no
correlation between sentinel node micrometastases and non sentinel node disease
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involved small numbers as shown in table 9. The number of patients given for each study
refers to the number ofpatients found to have a sentinel node containing micrometastatic
disease only.





Table 9: Prediction of non sentinel node metastases by sentinel node
micrometastases.
NSLN: non sentinel lymph node
A few studies have now been published looking at the effect of sentinel node
micrometastases on survival. Chagpar found that in 15 patients micrometastases of the
sentinel node identified by IHC there was no reduction in incidence of distant metastases,
overall survival or disease free survival (Chapgar et al. 2005). Sakaguchi performed RT
PCR on pooled sentinel and non sentinel nodes from 108 patients and found that 16%
expressed either CK19 or epithelial glycoprotein 2 and were therefore upstaged
(Sakaguchi et al. 2003). The 4 year survival for patients that had metastases identified by
RT PCR only was 100%, compared with 74% for patients with axillary metastases
diagnosed by conventional histology.
46
1.9.2. Summary
The evidence that axillary lymph node micrometastases influence survival is not clear
cut. Further research by long term follow up studies is required to answer this question
once and for all. Micrometastases have been identified by different authors using
different techniques - IHC, serial sectioning and now at the molecular level by RT PCR.
The ideal target for RT PCR analysis is the sentinel node(s), given that this is the node
most likely to harbour metastases and that only one or few nodes need to be processed.
There is, however, limited data on RT PCR evaluation of sentinel nodes from breast
cancer patients. The aim of this thesis was to use the technique to identify 3 different
breast cancer markers in sentinel lymph nodes from breast cancer patients. The number
of nodes 'upstaged' in relation to H&E histology were compared when different amounts






A study proposal was submitted to the research and development office of North
Glasgow University Hospitals NHS Trust. Ethical and financial approval were granted
on 4th November 2000 (project number 00SG011).
2.2. Patient selection and follow up
The selection criteria for sentinel lymph node biopsy were as follows. Patients were
those attending the one stop breast clinic at Glasgow Royal Infirmary with a solitary,
biopsy-proven invasive breast cancer. Clinically node positive patients and patients
undergoing immediate breast reconstruction were excluded. All diagnoses were
confirmed by core biopsy, following FNA and mammography +/- breast ultrasound.
When the patients returned for the results of their core biopsy, the operative options were
discussed with the patients along with an explanation of the study. Patients were given
an information leaflet (appendix 1) about the study to take home. Patients not
undergoing reconstruction were then admitted for surgery within the following 2 weeks.
All patients who participated in the study signed a patient consent form (appendix 2) in
addition to the usual consent form for surgery following admission to hospital.
From 1996 to 1999, 54 patients underwent sentinel node biopsy at Glasgow Royal
Infirmary, the preliminary results of which have been previously published (Flett et al.
1998). Sixty eight sentinel nodes were harvested from these patients (average 1.26
sentinel nodes per patient). These nodes were bisected and half the node stored at -80°C.
These half nodes were used for RT PCR analysis. These patients are referred to as
'group 1' below.
During a 16 month period beginning January 2001, 50 patients underwent sentinel node
biopsy at Glasgow Royal Infirmary and in these patients RT PCR was performed on a
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4pm section cut from each node leaving the remainder of the node for conventional
paraffin histology. These patients are referred to as 'group 2' below.
2.3. Sentinel lymph node biopsy
The sentinel node biopsies carried out in group 2 were all performed using a combination
of radioactivity and blue dye as previously described (Albertini et al. 1997, Cox et al.
1998, Frisell et al. 2001, Tafra et al. 2001, Smillie et al. 2001). All of these cases were
performed by the author together with a consultant breast surgeon or subspecialty breast
trainee. The sentinel node biopsies carried out in group 1 (prior to the start of the present
study) were performed using blue dye in all cases and radioactive colloid in 56% of the
cases.
The detection rates achieved and in particular the high number of negative preoperative
scintigrams compare poorly with many published series. The technique used to harvest
the sentinel nodes prospectively was based on the literature available at the time. Since
then different injection techniques have emerged. These cases represented an early phase
of the technique for the investigating institution and for the surgeons involved. The
technique has evolved in Glasgow Royal Infirmary and the results of the technique itself
today compare very differently with these early results. As the aim of this thesis was to
evaluate RT PCR in the analysis of sentinel nodes and comparison of these results with
conventional histology, all of the cases were included.
2.3.1. Lymphatic mapping
On the day prior to surgery the patients who had radioactive colloid used (all group 2 and
56% of group 1) were injected with technetium 99-labelled colloid (nanocoll). A
maximum dose of 40MBq was used, contained in a volume of l-2ml. This was injected
at 4 peritumoural sites (at 12, 3, 6 and 9 o'clock) and a small volume (<0.5ml) was
injected sub-dermallv over the tumour site. The injection technique was carried out in
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the same way for all patients and was always by the investigator for the group 2 patients.
Two hours later a scan was performed using a gamma camera to identify any axillary hot
spots. If any were seen, they were marked on the patients skin at the corresponding
point. Intra-operatively, a gamma-probe (C-Trak™) was used to identify radioactivity.
Any sentinel nodes removed were checked for radioactivity with the probe and if any
signal was obtained a 10 second count was determined using the probe and recorded.
2.3.2. Blue dye
After induction of general anaesthesia, patent blue dye was injected in all cases from
groups 1 and 2. 1ml dye was diluted up to a total volume of 5ml in 0.9% saline. Four
separate injections of 1ml each were then administered peritumourally at 12, 3, 6 and 9
o'clock and the final 1ml was injected subdermally over the tumour. The area was then
massaged briefly and the patient prepped. A minimum of 10 minutes elapsed between
injection and surgery.
2.3.3. Operative technique
Patients were prepped and draped in a standard fashion after injection of blue dye. The
patient's arm on the operating side was positioned at 90°. The gamma probe was
scanned over the patient's axilla before any incision was made. A curved incision was
then made in the lower axilla through skin and subcutaneous fascia. Dissecting scissors
were then used to explore the tissue. The probe was used at regular intervals to check for
any hot spots and blue stained lymphatic channels searched for in the cases where
radioactive colloid had been used. When either of these were identified they were traced
to the sentinel node. After the sentinel node had been excised the probe was used again
where appropriate to check for any residual activity and again blue stained lymphatics
searched for. In general, the dissection was carried from the lower axilla upwards.
Details of each operative case were recorded including start and finish times for the
procedure overall and the sentinel node biopsy itself.
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All patients in both groups proceeded to a level II axillary clearance after the sentinel
node had been harvested.
2.4. Pathology
Any identified sentinel nodes were taken immediately to the pathology department to
avoid unnecessary degradation of RNA.
2.4.1. Frozen section
The sentinel node was incised and a portion used to prepare 2 frozen sections. Wherever
possible, the hilum of the node was identified and the node was then bivalved along its
long axis. Sections were then cut at a thickness of 4pm and one was then stained with
H&E and given to the duty consultant pathologist for real time reporting. The remaining
section was put onto dry ice and transported immediately to a -80°C freezer where it
remained until the RNA was extracted.
2.4.2. Paraffin histology
All sentinel nodes were bisected and each half examined at 3 histological levels. All
other axillary nodes were bisected and each half examined at 1 level. Any node bigger
than 6mm in diameter was cut into 3mm slices and each slice examined at 3 levels for
sentinel nodes and 1 level for non sentinel nodes. This protocol has been ratified by the
most recent pathology guidelines from the NHS breast screening programme (2005).
2.5. RNA extraction
All plastic ware was pre-treated with di-ethylpyrocarbonate (DEPC) and autoclaved.
DEPC is a potent RNAse inhibitor. At all times latex gloves were used when handling
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tubes and tissue to prevent RNAse contamination. Gloves were changed frequently and
tubes kept closed whenever possible.
RNA extraction techniques were worked up using breast tissue prior to using sentinel
node tissue. The sentinel nodes were taken from theatre to the pathology department as
soon as they had been harvested. The frozen sections were prepared within 5 minutes of
the tissue arriving in the department. The section cut for RNA extraction was put onto
dry ice immediately and then stored at -80° C until use.
2.5.1. DEPC treatment of microfuge tubes/distilled water.
Distilled water was DEPC treated by adding 1.5ml DEPC to 1.5L water and mixing for
24 hours. Microfuge tubes were treated by immersing in 0.1% DEPC treated water
overnight. The tubes were then dried and autoclaved to eliminate residual DEPC.
2.5.2. RNA Isolation using the TRIzol (GibcoBRL Life Technologies) method
Small pieces (0.5-lg) of previously frozen breast tissue were crushed and immediately
placed in TRIzol (1ml TRIzol per lOOmg tissue) at room temperature. The tissue sample
in TRIzol was then homogenised using a PowerGen 125 tissue homogeniser (Fisher
Scientific) starting at 5000 RPM and gradually going up to approximately 20 000 RPM
over a period of 30-60 seconds at room temperature. This resulted in a homogeneous
solution with very few visible tissue pieces. The sample was then incubated at room
temperature for 5-10 minutes after homogenisation. The TRIzol/tissue homogenate was
then transferred to a 50ml centrifuge tube and centrifiiged at 10 000 RPM for 5-10
minutes at 4 °C. The upper fat layer was removed using a pasteur pipette. 0.2ml
chloroform per 1ml TRIzol reagent used was added and the tube shaken vigorously for
15-30 seconds by hand and incubated at room temperature for 5 minutes. The tube was
then spun at 10 000 RPM for 15 minutes at 4 °C. The upper aqueous phase, containing
the total RNA, was then removed and placed in a new 50ml centrifuge tube. The RNA
was then precipitated by adding 0.5ml isopropylalcohol per 1ml TRIzol reagent used.
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The sample was incubated at room temperature for 10 minutes, spun at 10 000 RPM for
10 minutes at 4°C and then left at -20°C overnight. The next day the tubes were
defrosted and spun at 12 000 RPM for 20 minutes at 4°C. The supernatant was then
decanted and the pellet washed once using 1ml 75% ethanol per 1ml TRIzol. This was
then spun at 7 500 RPM for 5 minutes at 4°C. The supernatant was decanted and the
pellet air dried at room temperature for 10-20 minutes. The pellet was then resuspended
in 50 pi DEPC-treated water and incubated at room temperature for 10 minutes and then
stored at 4°C.
When this technique was used to extract RNA from frozen sections, the sections were
scraped from the glass slide using a scalpel and added to tubes containing 1ml TRIzol.
The remaining steps followed as above.
2.5.3. RNA extraction using the Qiagen RNeasy kit
When RNA was extracted from breast tissue or sentinel nodes rather than frozen sections,
a maximum of 30mg tissue was used as suggested by die manufacturers. This tissue had
been snap frozen following operation and stored at -80°C to prevent RNA degradation.
The tissue was transferred from the freezer to a cold mortar and pestle and liquid nitrogen
added. The tissue was then ground to a powder and transferred to a 1.5ml microfuge tube
containing 600pl buffer RLT. Before use, (3 mercaptoethanol ((3 ME) was added to buffer
RLT (lOpl (3 ME per 1ml buffer RLT). The sample was further homogenised using a
white needle attached to a 5ml syringe - the sample was aspirated using the needle
multiple times. The lysate was then added to a QIA shredder column in a 2ml collection
tube and centrifuged for 2 minutes at 12 000 RPM. The lysate was then transferred to a
1.5ml microfuge tube and centrifuged for 3 minutes at 12 000 RPM. The supernatant
was then transferred to another microfuge tube and an equal volume of 70% ethanol
added and mixed by pipetting. The full volume was then added to a spin column sitting
in a 2ml collection tube and centrifuged for 15 seconds at 12 000 RPM. The flow
through was discarded and 700pi buffer RW1 added to the column. This was again
centrifuged for 15 seconds at 12 000 RPM and the flow through discarded. The column
54
was then transferred to a new 2ml collection tube and 500pl buffer RPE added to the
column. Buffer RPE was supplied as a concentrate and 4 volumes 100% ethanol was
added prior to use. The column was then centrifuged for 15 seconds at 12 000 RPM and
the flow through discarded. A further 500pl buffer RPE was added to the column and
centrifuged for 2 minutes at 12 000 RPM. The column was then placed in a new 2ml
collection tube and centrifuged for 1 minute at 12 000 RPM. The column was transferred
to another new collection tube and 30pi RNAse-free water pipetted onto the column.
This was centrifuged for 1 minute at 12 000 RPM to elute the RNA. RNA samples were
then immediately stored at -20°C.
When RNA extractions were performed from frozen sections, the tissue was scraped off
the glass slide using a scalpel blade into a 1.5ml microfuge tube containing 350pl buffer
RLT (with (3 ME added as before). The tube was then vortexed briefly and the lysate
pipetted onto the QIA shredder. The following steps were as described before.
2.6. Reverse transcription reaction.
Extracted RNA samples were reverse transcribed using the Omniscript ™ Reverse
Transcriptase kit. Template RNA solutions were thawed on ice. Primers were not
included in the kit and that used was oligo-dT primer (invitrogen). The primer solution
along with the other reagents - lOx buffer RT, dNTP mix, omniscript reverse
transcriptase and RNAse-free water were thawed at room temperature and then stored on
ice. Each solution was mixed by vortexing and centrifuged briefly to collect residual
liquid from the sides of the tubes. The following master mix was then prepared: 2gl lOx
buffer RT, 2pi dNTP mix, 2pl oligo dT, lpl reverse transcriptase and 8 pi RNAse-free
water. This mix was then vortexed for 5 seconds and centrifuged briefly. 5pl RNA
solution was then added to the master mix, vortexed for 5 seconds and centrifuged
briefly. The mixture was then incubated at 37°C for 1 hour.
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2.7. Polymerase chain reaction
The CAG repeat and (3 actin PCRs were worked up and well established in the laboratory.
These PCRs, which confirm the presence of house keeping genes, were used at various
points in the study to confirm the presence of cDNA after RNA extraction and reverse
transcription. The PCR reactions for the breast cancer markers CK 19, MUC 1 and CEA
had to be optimised and this process is detailed in chapter 6. In addition to these PCRs, 2
other reactions were tried at the start of this study. These were to determine the
expression of cytokeratin 20 (CK 20) and mammaglobin however after failing to get
these reactions working these markers were abandoned. Different master mixes, primer
sequences and PCR conditions were tried for each marker initially using control DNA
(extracted from blood) and then using DNA from breast tissue until a correctly sized band
was reliably produced. The reagents, primer sequences and conditions tried were taken
from previously published studies. In all cases the following reagents were added to a
microtube before placing on the PCR block - 2pl DNA, 2pl primer mix, lOpl mastermix
and 6pi water. The total volume in each tube was therefore 20pl. The master mixes,
primer sequences and conditions ultimately used together with the product sizes are
detailed in tables 10-13 below.
CAG repeat/p actin/CK 19 MUC 1 CEA
200 pi buffer IV * 200 pi 10 x buffer 0 200 pi 10 x buffer °
200 pi dNTPs 200 pi dNTPs 200 pi dNTPs
10 pi Taq polymerase n 10 pi Taq polymerase Q 10 pi Taq polymerase a
120 pi MgCl2 120 pi MgCl2
470 pi H20 590 pi H20 470 pi H20
Table 10: PCR master mixes (total volume for each = 1ml).
*Advanced Biotechnologies (containing 15mM MgCl2)
0 Qiagen (containing 1,5mM MgCl2)
a Advanced Biotechnologies
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PCR primer sequences reference
CAG repeat 5'-TCC GCG AAG TGA TCC
AGA AC-3'; 5'-CTT GGGG AGA
ACC ATC CTC A -3'
Mir et al. 2002
P actin 5'-TAT CCA GGC TGT GCT ATC
CCT GTA C-3'; 5'-CTT GAT
GAG GTA GTC AGT CAG GTC
C-3'
designed in house
CK 19 5'-AGG TGG ATT CCG CTC
CGG GCA-3'; 5'-ATC TTC CTG
TCC CTC GAG CA-3'
Noguchi et al. 1996
MUC 1 5'-CGT CGT GGA CAT TGA
TGG TAC C-3'; 5'-GGT ACC
TCC TCT CAC CTC CTC CAA-3'
Bosticketal. 1998
CEA 5'-TCT GGA ACT TCT CCT GGT
CTC TCT CAG CTG G-3'; 5'-
GGG CCA CTG TCG GCA TCA
TGATTG -3'
Ooka et al. 2000
Table 11: PCR primer sequences
p actin/MUC 1/CEA
step 1 95°C x 5 minutes
step 2 95 °C x 1 minute
step 3 50°C x 1 minute
step 4 72°C x 1 minute
(steps 2-4 x 35 cycles)
step 5 72°C x 10 minutes
CAG repeat
step 1 95°C x 1 minute
step 2 95°C x 1 minute
step 3 50°C x 1 minute
step 4 72°C x 1 minute
(steps 2-4 x 25 cycles)
step 5 72°C x 10 minutes
CK 19
step 1 95°C x 5 minutes
step 2 95°C x 1 minute
step 3 60°C x 1 minute
step 4 72°C x 2 minutes
(steps 2-4 x 25 cycles)
step 5 72°C for 10 minutes
Table 12: PCR conditions
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PCR product Size
CAG repeat 163 bp
(3 actin 169 bp
CK 19 160 bp
MUC 1 288 bp
CEA 160 bp
Table 13: PCR product sizes
The presence of the three markers was determined in the sentinel nodes from groups 1
and 2. The primary tumours were not examined. The aim of this study was to compare
the presence of the markers with each other and with conventional histology of the
sentinel nodes. If the technique were to prove sensitive in the detection of metastases
then RT PCR using one or a combination of these markers may have a staging role in
clinical practice. In the clinical setting, the marker expression by the sentinel nodes and
not the primary tumour would be determined by RT PCR as the aim of the technique is to
detect axillary metastases. Accepting that CEA expression by breast cancers in particular
is variable, the combination of the results of two or all three markers should identify
metastatic disease if the technique is a reliable tool.
2.8. Agarose gel electrophoresis
A stock solution of 50x TAE (tris acetic acid EDTA) was prepared as follows:
242g tris acetic acid was added to 500ml distilled water. 100ml 0.5M Na2EDTA (pH 8)
and 57ml glacial acetic acid were then added and the total volume adjusted to 11. To
make lx TAE this solution was diluted 50 times in distilled water.
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Loading buffer was prepared as follows:
30ml 30% glycerol was added to 70ml water. 25mg 0.25% xylene cyanol and 25mg
0.025% bromophenol blue were then added. Before loading samples to an agarose gel,
5pi of loading buffer was added to each sample.
A 2% agarose gel was prepared as follows:
5g agarose was added to 250ml lx TAE and microwaved for 2/i minutes. This was left
to cool and then lOpl ethidium bromide solution (lOmg/ml) was added and mixed gently.
The solution was then poured into a gel rig and left to set. Samples (with loading buffer
added) were then placed in the wells. In one lane lOObp DNA ladder was run (lpl ladder
+ 9pl loading buffer) in order to size any bands seen. The gel was then run for







There were 54 patients from whom 68 half sentinel nodes had been stored at -80°C. All
patients had unilateral cancers and so the number of procedures was equal to the number
ofpatients. All patients were female. Thirty one patients underwent mastectomy and 23
underwent breast conserving surgery. The results for this group are given in detail below
(table 14) and then summarised (table 15).
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pt no. age no. wts. of no. no. T type T size grade NPI
SLN '/2 +ve other
SLNs SLN +ve
LN
1 67 1 0.27g 0 0/10 IDC 80mm 3 5.6
2 47 2 0.1 lg 1 0/8 IDC 12mm 3 5.24
0.15g
3 86 1 0.99g 0 0/8 IDC 35mm 3 4.7
4 48 1 0.27g 0 0/10 IDC 12mm 1 2.24
5 56 1 0.16g 0 0/8 IDC 14mm 2 3.28
6 71 1 0.19g 0 0/15 IDC 30mm 2 3.6
7 65 1 0.18g 0 0/12 IDC 55mm 2 4.1
8 50 1 0.27g 0 0/23 IDC 28mm 2 3.56
9 35 2 0.18g 0 0/11 IDC 10mm 1 2.2
0.9 lg
10 64 2 0.14g 0 0/13 ILC 16mm 2 3.32
0.1 Og
11 69 1 0.15g 1 0/15 IDC 29mm 3 5.58
12 53 2 0.07g 0 0/15 ILC 13mm 1 2.26
1-lg
13 73 2 0.3g 0 0/16 IDC 35mm 2 3.7
0.14g
14 49 1 0.92g 0 0/9 IDC 16mm 2 3.32
15 79 3 0.37g 3 8/22 IDC 36mm 3 6.72
04 lg
l-2g
16 73 1 0.42g 0 0/8 ILC 25mm 2 3.5
17 76 1 0.33g 0 0/18 tubular 20mm 1 2.4
18 43 1 0.15g 0 1/12 IDC 11mm 2 4.22
19 50 1 0.26g 0 0/9 IDC 6mm 1 2.12
20 73 1 0.58g 0 0/17 IDC 22mm 2 3.44
21 53 1 0.05g 0 0/17 IDC 22mm 3 4.44
22 68 1 0.48g 0 0/8 IDC 21mm 2 3.42
23 64 1 0.62g 1 0/14 IDC 40mm 3 5.8
24 35 1 O.lg 0 0/15 IDC 12mm 3 4.24
25 47 0.22g 0 0/26 IDC 15mm 1 2.3
0.38g
26 73 1 0.09g 0 0/16 IDC 20mm 2 3.4
27 39 1 0.26g 0 1/19 IDC 13mm 3 5.26
28 56 1 0.17g 0 0/6 IDC 18mm 1 2.36
29 64 1 0.18g 0 0/14 IDC 15mm 2 3.3
30 72 1 0.3g 0 0/10 IDC 35mm 2 3.7
31 63 1 0.43g 0 0/15 IDC 18mm 3 4.36
32 46 1 0.6g 0 0/13 tubular 10mm 1 2.2
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T type T size grade NPI
33 33 1 0.95g 0 0/15 IDC 16mm 3 4.32
34 73 2 0.14g
0.09g
0 0/13 IDC 9mm 1 2.18
35 59 1 0.28g 0 0/14 IDC 12mm 3 4.14
36 50 1 0.05g 0 8/18 ILC 15mm 2 5.3
37 54 2 0.07g
0.15g
0 0/16 IDC 23mm 1 2.46
38 56 1 0.08g 0 0/17 IDC 24mm 1 2.48
39 48 2 0.10g
0.25g
0 0/30 IDC 15mm 3 4.3
40 78 1 0.06g 0 0/11 ILC 50mm 2 4
41 56 1 0.97g 0 0/14 IDC 6mm 2 3.12
42 82 1 0.29g 0 0/14 IDC 25mm 3 4.5
43 69 1 0.06g 0 0/10 IDC 22mm 2 3.44
44 53 2 0.5g
0.03g
1 0/10 IDC 30mm 3 5.6
45 45 2 O.llg
0.21g
0 0/14 IDC 10mm 3 4.2
46 55 2 0.3g
0.35g
0 0/5 IDC 14mm 2 3.28
47 39 1 0.13K 0 0/19 IDC 10mm 2 3.2
48 71 1 0.5g 0 0/12 mucoid 14mm 1 2.28
49 45 1 0.07g 0 0/16 IDC 14mm 2 3.28
50 80 1 0.32g 1 1/11 IDC 31mm 2 4.62
51 56 1 0.07g 0 0/9 IDC 22mm 2 3.44
52 65 1 0-5 lg 0 2/12 IDC 25mm 3 5.5
53 63 1 0.04g 0 0/11 IDC 13mm 1 2.26
54 69 1 0.27g 0 0/18 IDC 19mm 2 3.38
Table 14: Group 1 data
number sentinel lymph nodes(no. SLN); number positive sentinel lymph nodes (no.
+ve SLN); weights of half sentinel lymph nodes (wts. Vi SLN); number positive non
sentinel axillary nodes (no. other +ve LN); tumour type (T type); tumour size (T
size); grade; Nottingham Prognostic Index (NPI)
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Group 1 54 patients
age range 33-86 (average 58.8)
% SLN only positive 7.4% (4/54)
% NSLN only positive 3.7% (2/54)
% SLN + NSLN positive 7.4% (4/54)
FNR 40% (4/10)
% node positivity 10/54(18.5%)
tumour size 6-80mm (average 21.4mm)
% Grade I / II / III 24.1%/44.4%/31.5%
% invasive ductal carcinoma 85.2
NPI 2.12-6.72 (average 3.72)
Table 15: Group 1 - summary of patient details
3.2. Group 2
During a 16 month period sentinel node biopsy was attempted in 64 patients. One patient
had bilateral cancers making a total of 65 procedures. A sentinel node was detected in 50
patients giving a detection rate of 77%. The bilateral case had a sentinel node detected
on one side only and so the total number of procedures included in the study was also 50.
Of the 15 procedures where no sentinel node was detected, the age range was 52 to 72
(average 62). Tumour size ranged from 10 to 50 mm (average 20.4mm). In 9 cases
(60%) the tumour was medially located. The pre-operative scan was negative in 12 out
of 15 procedures (80%). Of the 3 positive scans, the hot spot was identified in the
internal mammary chain in 2 cases and the axilla in one case. The overall axillary node
status was positive in 10 out of 15 cases (66.6%) and in 3 of these cases the axilla was
found to be macroscopically positive at operation. In addition 3 of the cases where no
sentinel node was found were significantly overweight. The dose of radioactivity given
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ranged from 23 to 40 MBq with an average dose of 37.7 MBq per patient. The range in
time delay between injection of radioactive colloid and the operation start time was 18 to
25 hours (average delay 21.4 hours). The delay between injection of blue dye and the
operation start time ranged from 10 to 15 minutes with an average delay of 11.2 minutes.
Of the 50 patients in whom a sentinel node was found, one was male. Thirty cancers
were left sided and 20 right sided. Twenty nine patients (58%) underwent breast
conserving surgery while 21 (42%) underwent mastectomy. In 46 cases (92%) the
histological type was invasive ductal carcinoma as shown below and of the remaining 4
cases, 2 were invasive lobular carcinomas and 2 were special type tubular/mucoid
carcinomas. The results from the 50 patients where a sentinel node was harvested are
given in detail below (table 16) and then summarised (table 17). The 15 procedures from
which no sentinel node was harvested have not been included in this table and will not be
discussed any further.
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T type T size grade NPI
1 58 1 0 0/12 IDC 9mm 1 2.18
2 53 2 2 6/14 IDC 19mm 3 6.38
3 57 1 0 0/10 IDC 9mm 1 2.18
4 71 1 0 0/10 IDC 20mm 3 4.4
5 78 1 0 0/13 tubular 20mm 1 2.4
6 62 1 1 1/17 IDC 16mm 2 4.32
7 55 1 0 0/10 IDC 9mm 2 2.18
8 70 1 0 0/21 IDC 34mm 3 4.68
9 36 1 0 0/16 IDC 15mm 2 3.3
10 52 1 1 0/12 IDC 10mm 1 2.2
11 55 0 0/14 IDC 23mm 3 4.48
12 37 1 1 1/17 IDC 15mm 3 5.3
13 56 2 0/11 IDC 15mm 2 4.3
14 52 1 1 20/23 IDC 30mm 3 6.6
15 61 1 0 0/13 IDC 40mm 1 2.8
16 72 1 0 0/14 IDC 15mm 2 3.3
17 75 1 1 11/16 IDC 20mm 1 4.4
18 52 1 1 0/12 IDC 30mm 3 4.6
19 58 1 0/13 IDC 20mm 1 3.4
20 81 1 1 0/23 IDC 35mm 2 4.7
21 72 0 0/17 IDC 27mm 2 3.54
22 54 1 0 0/6 IDC 15mm 2 3.3
23 36 1 1 6/21 IDC 32mm 3 6.64
24 82 0 0/6 IDC 17mm 2 3.34
25 84 1 1 1/13 IDC 47mm 3 5.94
26 50 1 0 1/15 IDC 15mm 2 4.3
27 55 1 0 1/20 IDC 13mm 3 5.26
28 78 1 0/5 IDC 15mm 2 4.3
29 74 1 1 2/14 ILC 33mm 2 4.6
30 57 1 0 0/14 IDC 18mm 3 4.36
31 38 1 0 0/13 IDC 12mm 3 4.24
32 79 1 1 11/23 IDC 54mm 3 7.08
33 51 1 0 0/12 tubular 25mm 1 2.5
34 73 1 0 0/13 IDC 45mm 3 4.9
35 61 1 0 9/13 IDC 26mm 3 6.52
36 60 1 1 0/16 IDC 25mm 2 4.5
37 66 1 1 0/16 IDC 20mm 2 4.4
38 79 1 0 0/14 IDC 20mm 3 4.4
39 59 1 1 1/10 IDC 16mm 2 4.32
40 72 1 0 2/14 IDC 12mm 3 5.24
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T type T size grade NPI
41 70 1 1 1/14 IDC 33mm 3 5.66
42 67 1 0 0/13 IDC 38mm 3 4.72
43 70 1 0/12 IDC 30mm 3 5.6
44 65 1 1 0/8 IDC 13mm 3 5.26
45 56 1 0 0/11 IDC 22mm 2 3.44
46 53 1 10/22 ILC 32mm 2 5.64
47 72 1 0 0/14 IDC 22mm 3 4.44
48 65 1 0 0/20 IDC 23mm 3 4.46
49 57 1 0 0/16 IDC 15mm 2 3.3
50 64 1 1 0/15 IDC 42mm 3 5.8
Table 16: Group 2 data
age; number sentinel lymph nodes (no. SLN); number positive sentinel lymph nodes
(no. +ve SLN); number positive non sentinel axillary lymph nodes (no. other +ve
LN); tumour type (T type); tumour size (T size); grade; Nottingham Prognostic
Index (NPI)
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Group 2 50 patients
age range 36-84 (average 62.3)
% SLN only positive 22% (11/50)
% NSLN only positive 8% (4/50)
% SLN + NSLN positive 24% (12/50)
FNR 14.8% (4/27)
Overall % node positivity 54% (27/50)
tumour size 9-54mm (average 31.5mm)
% grade I / II / III 16%/36%/48%
% invasive ductal carcinoma 92% (46/50)
% oestrogen receptor positive 82% (41/50)
NPI 2.18-7.08 (average 4.5)
Table 17: Group 2 - summary of patient details
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3.3. Summary and comparison of groups 1 and 2
The total number of patients included in the study was therefore 104. From these patients
128 sentinel nodes were harvested. In total 52 (50%) of patients underwent mastectomy
and 52 underwent breast conserving surgery. Table 18 compares the results for the 2
groups:
Group 1 (54 patients) Group 2 (50 patients)
age range 33-86 (average 58.8) 36-84 (average 62.3)
% SLN positive 11.1% (6/54) 46% (23/50)
% overall node positivity 18.5% 54%
FNR 40% (4/10) 14.8% (4/27)
tumour size 6-80mm (av. 21.4mm) 9-54mm (av.31.5mm)
% grade I / II / III 24.1%/44.4%/31.5% 16%/36%/48%
% invasive ductal Ca 85.2% 92%
NPI 2.12-6.72 (av. 3.72) 2.18-7.08 (av. 4.5)
Table 18: Comparison of groups 1 and 2
Although irrelevant to the purposes of this study, the patients in group 2 which were
accrued prospectively during the study represent a prognostically poorer group compared
to group 1. The group 2 tumours were generally larger, of higher grade and had a higher
rate of axillary disease as detected by paraffin histology. This is reflected in the overall
higher average NPI of 4.5 compared with 3.72 in group 1.
One would expect around one third of all breast cancers to be node positive and so group
1 represents a group with fewer than predicted node positive cancers and group 2 has
more node positive cases. The patients from group 2 represented all the clinically node
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negative patients who presented during the study period agreeing to participate and in
whom a sentinel node was identified. The patients were not selected in any other way.
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Chapter 4
Sentinel lymph node biopsy technique
results
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The total number of sentinel nodes harvested from the 54 patients in group 1 was 68
(mean number of sentinel nodes per patient 1.26) and from the 50 patients in group 2 was
60 (mean 1.2).
Sentinel nodes from the 50 patients in group 2 were identified using the combination of
radioactive colloid and blue dye. The time taken to identify a sentinel node ranged from
3 minutes to 30 minutes (median 16.5 minutes); the average time taken was 16.5 minutes.
The time for the entire procedure ranged from 45 minutes to 115 minutes (median 80
minutes) with an average operation time of 75.6 minutes.
4.1. Lymphatic mapping
The dose of nanocoll injected ranged from 19 to 40 MBq (median 29.5 MBq); the
average injected dose 36.6 MBq. The delay between injection of radioactive colloid and
surgery ranged from 5.5 to 25 hours (median 15.25 hours); the average delay was 20.9
hours.
In 34 of the 50 patients comprising group 2 (68%) the pre-operative scan did not show
any hot spots. In 15 patients one or more hot spots were seen in the axilla on the scan. In
the remaining one patient 2 internal mammary hot spots were visualised. Of the 15
procedures also carried out in group 2 where no sentinel node was identified, 12 had a
negative scan. Overall therefore the pre operative scan was negative in 70.8% (46/65
procedures).
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Figure 1: Scan showing hot spot in left axilla. The injection site in the breast has
been masked.
Thirty sentinel nodes from 26 patients were radioactive. The majority - 83.3% (25
nodes) - of these nodes were also blue with the remaining 16.6% (5 nodes) being 'hot
only'. The 10 second count from the hot nodes ranged from 8 to 439; the average 10
second count was 144.5.
Of the 15 patients in whom an axillary hot spot had been seen on the scan and the patient
marked, 14 went on to have at least one hot sentinel node harvested. In the other patient,
one blue only sentinel node was found and the failure to identify a hot node from this
patient suggests that at least one other sentinel node was missed ie not detected. There
were 13 hot sentinel nodes from 11 patients who had had negative pre-operative scans.
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4.2. Blue dye
The time delay between injection of blue dye and the start of the procedure ranged from
10 minutes to 15 minutes with an average delay of 10 minutes 23 seconds. Fifty five
sentinel nodes from 48 patients were blue. Thirty of these nodes were blue only and, as
above, 25 nodes were hot and blue. Figure 2 demonstrates a case where blue stained
lymphatics were identified and traced to a blue sentinel node which is shown in figure 3
after excision.
Figure 2: Intraoperative photo showing dissection of tissues following incision of
skin in lower axilla to find blue stained lymphatic channels
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Figure 3: Photograph showing blue sentinel node and 2 blue stained afferent
lymphatic channels
4.3. Summary
For the group 2 patients, more sentinel nodes were identified by blue dye than by






5.1. Intra operative frozen section
Intra-operative frozen section was performed on 43 of the 68 sentinel nodes from group 1
and on all 60 sentinel nodes from group 2. For the group 2 cases, this was reported intra
operatively and the results telephoned to the operating theatre with a time range of 19 to
30 minutes - the average time for reporting of results was 25 minutes. The frozen section
was reported as positive in 19 sentinel nodes and negative in 84 sentinel nodes. Seven
sentinel nodes from 7 patients had a negatively reported frozen section but subsequent
H&E histology of the node was positive. This represents a false negative rate for frozen
section of 21.2% (7/33) on a node basis. There were no false positive frozen section
results.
5.2. Post operative (paraffin) histology
In total, 95 sentinel lymph nodes from 75 patients were H&E negative and 33 sentinel
lymph nodes from 29 patients were H&E positive. The overall axillary node status was
positive in 37 out of 104 patients (35.6%). Of the node positive patients, 15 had a
positive sentinel node and no other positive nodes; 14 had a positive sentinel node and
other positive axillary nodes and the remaining 8 patients had a negative sentinel node
but other non-sentinel axillary nodes that were involved. This represents a false negative
rate, based on H&E histology, of 21.6% (8/37 patients).
The total number of axillary nodes obtained, including the sentinel nodes, ranged from 3
to 24 per patient with an average of 14.75 nodes per patient.
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Figure 4: H&E positive sentinel lymph node
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5.3. Summary









Table 19: H&E histology results for groups 1 and 2 combined
SLN: sentinel lymph node






6.1. RNA extraction and reverse transcription
6.1.1. RNA extraction using TRIzoI method
RNA extraction was initially attempted using the TRIzol method as described. The initial
attempt was made using 0.6g frozen normal breast tissue. A pellet was obtained after the
overnight incubation and the resuspended sample used in a CAG repeat PCR. The
subsequent RNA gel which was run with and without 2M NaOH added to the sample
wells was blank. The technique was therefore repeated using larger tissue samples - 0.8g
and then lg frozen breast tissue but again no bands were obtained after CAG repeat PCR.
Despite not achieving success in extraction ofRNA from breast tissue, the technique was
tried using frozen sections. Initially 4 x 10pm frozen sections of breast tissue were
scraped off into the TRIzol and the technique then continued as before but again no bands
were seen on running the resuspended pellet samples on a gel in wells with and without
NaOH.
The next step was to attempt a reverse transcription reaction using the superscript ™
system on the samples obtained from the RNA extraction from frozen sections. CAG
repeat and (3 actin PCRs were then performed but no bands were seen on subsequent gel
electrophoresis.
6.1.2. RNA extraction using Qiagen RNeasy kit
Following the lack of success in extracting RNA either from solid tissue or frozen
sections, another method was tried. The Qiagen RNeasy kit was used initially on a 30mg
sample ofnormal breast tissue. A reverse transcription reaction was carried out using the
omniscript™ system and a (3 actin PCR confirmed the presence of cDNA. The successful
extraction of RNA and subsequent successful reverse transcription allowed both of these
steps to be carried out on the 68 frozen half sentinel nodes (group 1). The weight of each
81
half frozen node was determined before RNA extraction. The range of these weights was
0.03g to 1.2g (average 0.3 lg).
RNA extraction was then worked up on frozen sections. Initially lOx 4pm sections were
cut fresh from a breast cancer specimen and RNA extraction and reverse transcription
steps carried out as before. Correctly sized bands confirmed the presence of cDNA after
(3actin PCR. The same process was then carried out using 4x 4pm sections and then a
single section and again bands were seen on the gel. This allowed the process to be
carried out on the prospectively collected frozen sections (group 2) as they were obtained.
Again, reverse transcription was always carried out immediately to allow confirmatory
CAG repeat and |3 actin PCRs.
6.2. Polymerase chain reactions
6.2.1. Cytokeratin 19
The CK 19 PCR was the first reaction to be worked up. Initially this was done using
control DNA extracted from blood.
The conditions, primer sequences and master mix used have been detailed in the
materials and methods chapter but before these were arrived at alternative master mixes
containing a different buffer ('buffer II') and different concentrations of Taq polymerase
were tried. Annealing temperatures of 50°C and 55°C were also tried.
Using the conditions described previously a single band was reliably produced on a gel
however this was found to be approximately 700bp in size, differing from the 460bp size
stated in the literature (Noguchi et al. 1996). However when the sequence of the whole
gene was examined the length of the product between the primers was found to be 716bp
and when the reaction was then tried on samples where RNA was first extracted from
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breast tissue and then a reverse transcription step performed, a correctly sized 460bp
product was obtained.
6.2.2. Mucin 1
The PCR for MUC 1 was worked up using samples where RNA had been extracted from
breast tissue, reverse transcription performed and presence of cDNA confirmed. Before a
single correctly sized band was reliably produced different master mixes and PCR
conditions were tried. Master mixes containing different buffers - buffer IV and Q buffer
were used and annealing temperatures of 55°C and 60°C tried. The conditions and
reagents ultimately used were shown above.
6.2.3. Carcinoembryonic antigen
The PCR for CEA took the longest time to work up and looking back this is almost
certainly due to the fact that many of the cDNA samples used in the work up of the
reaction were probably CEA negative. Many conditions and master mixes were tried
before a single band was produced and indeed different primers were also tried. The
initial primer set was as follows: 5-GGG CCA CTG TCG GCA TCA TGA TTG-3' and
5'-TGT AGC TGT TGC AAA TGC TTT AAG GAA GAA GC-3\ The corresponding
product size was 131 bp. Master mixes containing buffer IV and Q buffer and annealing
temperatures of 51, 53, 55 and 60°C were all tried at various times. Eventually new
primers were ordered, comprising the original reverse primer but a new forward primer
and using these with the lOxbuffer master mix containing additional MgCh and





For each of the 3 markers studied, the sensitivity, specificity and false negative rate have
been calculated. The term 'false negative' has already been used above to describe
histologically negative sentinel nodes in patients with other positive axillary nodes and is
being used here in another context. In order to calculate these, the number of true
positives, true negatives, false positives and false negatives must be determined. These
have been defined as shown in table 20 below.
H&E + H&E -
RT PCR + True positive False positive
RT PCR- False negative True negative
Table 20: Definition of true negatives, false negatives, true positives and false
positives by RT PCR compared to H&E
7.1. Cytokeratin 19
7.1.1. Group 1
CK 19 expression was found in 25 of the 68 half nodes (36.8%) from group 1. Of the 25
nodes, 16 were from patients that had H&E negative sentinel and non-sentinel nodes,
representing an upstaging rate of 23.5%. Seven nodes agreed with positive histology and
2 sentinel nodes were false negatives (1 with another positive sentinel node and the other
with another positive non-sentinel node). Ofthe 43 sentinel nodes that did not express
CK 19, there was 1 node that had been H&E positive. This node may have represented a
failure of RT PCR and the expression of CK 19 by this node could, in retrospect, have
been checked by immunohistochemistry. Of the remaining 42 nodes where negative CK
19 expression did correlate with negative H&E histology, there were 4 false negatives
that were not upstaged (1 where another sentinel node had been positive and 1 where
another non-sentinel node had been positive).
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The sensitivity of CK 19 expression was therefore 90%, specificity 72.4% and false
negative rate 10%. The concordance between CK 19 expression and H&E histology was
72% (49/68 nodes).
7.1.2. Group 2
Of the 60 sentinel nodes examined, 15 nodes (25%) were found to express CK 19 by
PCR and 45 (75%) were found not to express CK 19. Of the 15 CK 19 positive nodes, all
had positive paraffin histology. Of the 45 CK 19 negative nodes, 36 had a histologically
negative sentinel node but the remaining 9 nodes had been positive by H&E. Again, CK
19 expression by these nodes could have been further validated by
immunohistochemistry. No patients were therefore upstaged by CK 19 PCR and in
particular none of the false negative sentinel nodes were upstaged.
This represents a sensitivity of 62.5%, specificity 100% and false negative rate 37.5%.
The concordance between the H&E histology of the sentinel node and CK 19 PCR was
85% (51/60).
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lane 1 2 3 4 5 6
Figure 5: Gel photo for CK 19 PCR
Lanes 1 and 6 show a lOObp DNA ladder. Lanes 2 and 3 display DNA from one sentinel
node where lane 2 shows a 169bp (3 actin band and lane 3 shows a 460bp CK 19 band.
DNA from a different sentinel node has been run in lanes 4 and 5 and lane 4 confirms





MUC 1 expression was found in 32 out of 68 half nodes (47%). Thirty six nodes (53%)
did not express MUC 1. Of the 32 nodes that were MUC 1 positive, 5 had been positive
by H&E histology. The remaining 27 sentinel nodes (39.7%) therefore had been
upstaged - these included 2 false negative sentinel nodes - 1 with another sentinel node
that was H&E positive and 1 with other positive non-sentinel nodes. Of the 36 nodes that
were MUC 1 negative, 3 had been H&E positive and 33 H&E negative. There were 4
false negative sentinel nodes included in this group that were not upstaged by MUC 1
PCR.
The sensitivity was therefore 62.5%, specificity 55% and false negative rate 37.5%.
Concordance between H&E histology and MUC 1 expression was 55.9% (38/68 nodes).
7.2.2. Group 2
MUC 1 expression was found in 47 out of 60 nodes (78.3%). Thirteen nodes (21.6%)
were MUC 1 negative. Of the nodes that expressed MUC 1,21 nodes were also positive
by paraffin histology. Twenty six sentinel nodes (43.3%) were upstaged by MUC 1 PCR.
Twenty two of these nodes were H&E negative but 4 were false negatives - 2 with other
non-sentinel axillary node(s) involved and 2 with another sentinel node that was H&E
positive. Of the 13 nodes that were not found to express MUC 1, 11 were also H&E
negative but the other 2 nodes were H&E positive.
The sensitivity was therefore 91.3%, specificity 29.7% and false negative rate 8.7%. The
overall concordance between H&E histology and MUC 1 expression was 53.3%.
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lane 12 3 4
Figure 6: Gel photo for MUC 1 PCR
Lane 1 shows a lOObp DNA ladder. Lanes 2 and 3 display DNA from one sentinel node




CEA expression was found in 18 out of 68 half nodes (26.5%). Fifty sentinel nodes
(73.5%) did not express CEA. Of the 18 CEA positive nodes, only 1 had been EI&E
positive. The 17 sentinel nodes (25%) that were upstaged by CEA PCR included 1 false
negative. Of the 50 CEA negative nodes, the H&E histology had also been negative in
43 cases and this group included 5 false negative nodes - 3 with other non-sentinel node
involvement and 2 with another positive sentinel node. There were 7 cases where H&E
was positive but no CEA expression detected.
The sensitivity was therefore 12.5%, specificity 71.7% and false negative rate 87.5%.
Overall concordance between H&E histology and CEA expression was 64.7% (44/68
nodes).
7.3.2. Group 2
CEA expression was found in 10 out of 60 nodes (16.7%). Fifty nodes (83.3%) did not
express CEA. Of the 10 nodes that were CEA positive, 6 were H&E positive but 4 were
H&E negative and so 6.7% of all sentinel nodes were upstaged by CEA PCR. None of
these upstaged nodes represented any of the false negatives by H&E. Of the 50 nodes
that were found not to express CEA, 33 agreed with negative paraffin histology and these
included the false negatives - 5 cases where other non-sentinel nodes were positive and 2
cases where another sentinel node was positive. In 17 nodes CEA expression was not
found but H&E histology was positive.
The sensitivity was therefore 26.1%, specificity 89.2% and false negative rate 73.9%.
The overall concordance between H&E histology and CEA expression was 65%.
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lane 12345
Figure 7: Gel photo for CEA PCR
Lanes 1 and 5 show a lOObp DNA ladder. Lanes 2 and 3 display DNA from one sentinel
node where lane 2 shows a 169bp (3 actin band and lane 3 shows a 166 bp CEA band.
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7.4. Summary of RT PCR results
Tables 21 and 22 below display the patient and tumour data from groups 1 and 2
respectively that were previously shown (tables 14 and 16) with the marker expressions





















1 67 1 0.27g 0 0/10 IDC 80mm 3 5.6 + + -
2 47 2 O.llg
0.15g





3 86 1 0.99g 0 0/8 IDC 35mm 3 4.7 + + -
4 48 1 0.27g 0 0/10 IDC 12mm 1 2.24 - - +
5 56 1 0.16g 0 0/8 IDC 14mm 2 3.28 - - -
6 71 1 0.19g 0 0/15 IDC 30mm 2 3.6 + + -
7 65 1 0.18g 0 0/12 IDC 55mm 2 4.1 - + -
8 50 1 0.27g 0 0/23 IDC 28mm 2 3.56 - + -
9 35 2 0.18g
0.91g
0 0/11 IDC 10mm 1 2.2
+
+ -
10 64 2 0.14g
0.10g




11 69 1 0.15g 1 0/15 IDC 29mm 3 5.58 + - -
12 53 2 0.07g
1 lg
0 0/15 ILC 13mm 1 2.26 - - +
13 73 2 0.3g
0.14g
0 0/16 IDC 35mm 2 3.7 -
+
+
14 49 1 0.92g 0 0/9 IDC 16mm 2 3.32 + + -
15 79 3 0.37g
04 lg
l-2g







16 73 1 0.42g 0 0/8 ILC 25mm 2 3.5 - - -
17 76 1 0.33g 0 0/18 tubular 20mm 1 2.4 - - -
18 43 1 0.15g 0 1/12 IDC 11mm 2 4.22 - - +
19 50 1 0.26g 0 0/9 IDC 6mm 1 2.12 - - +
20 73 1 0.58g 0 0/17 IDC 22mm 2 3.44 - - +
21 53 1 0.05g 0 0/17 IDC 22mm 3 4.44 - - +
22 68 1 0.48g 0 0/8 IDC 21mm 2 3.42 + + -
23 64 1 0.62g 1 0/14 IDC 40mm 3 5.8 + + -
24 35 1 O.lg 0 0/15 IDC 12mm 3 4.24 - - +
25 47 2 0.22g
0.38g
0 0/26 IDC 15mm 1 2.3 -
+
+





















27 39 1 0.26g 0 1/19 IDC 13mm 3 5.26 - - -
28 56 1 0.17g 0 0/6 IDC 18mm 1 2.36 - - -
29 64 1 0.18g 0 0/14 IDC 15mm 2 3.3 - + +
30 72 1 0.3g 0 0/10 IDC 35mm 2 3.7 + - +
31 63 1 0.43g 0 0/15 IDC 18mm 3 4.36 + + -
32 46 1 0.6g 0 0/13 tubular 10mm 1 2.2 + - +
33 33 1 0.95g 0 0/15 IDC 16mm 3 4.32 + + -
34 73 2 0.14g
0.09g
0 0/13 IDC 9mm 1 2.18 - + -
35 59 1 0.28g 0 0/14 IDC 12mm 3 4.14 - - -
36 50 1 0.05g 0 8/18 ILC 15mm 2 5.3 + + -
37 54 2 0.07g
0.15g
0 0/16 IDC 23mm 1 2.46 - +
+
38 56 1 0.08g 0 0/17 IDC 24mm 1 2.48 - + +
39 48 2 0.1 Og
0.25g
0 0/30 IDC 15mm 3 4.3 - - -
40 78 1 0.06g 0 0/11 ILC 50mm 2 4 - + +
41 56 1 0.97g 0 0/14 IDC 6mm 2 3.12 + - -
42 82 1 0.29g 0 0/14 IDC 25mm 3 4.5 - - -
43 69 1 0.06g 0 0/10 IDC 22mm 2 3.44 - - -
44 53 2 0.5g
0.03g
1 0/10 IDC 30mm 3 5.6 - - -
45 45 2 0.1 lg
0.21g
0 0/14 IDC 10mm 3 4.2 + + +
46 55 2 0.3g
0.35g





47 39 1 0.13g 0 0/19 IDC 10mm 2 3.2 - - -
48 71 1 0.5g 0 0/12 mucoid 14mm 1 2.28 - - -
49 45 1 0.07g 0 0/16 IDC 14mm 2 3.28 - - -
50 80 1 0.32g 1 1/11 IDC 31mm 2 4.62 + - -
51 56 1 0.07g 0 0/9 IDC 22mm 2 3.44 - - -
52 65 1 0.5 lg 0 2/12 IDC 25mm 3 5.5 - - -
53 63 1 0.04g 0 0/11 IDC 13mm 1 2.26 - + -
54 69 1 0.27g 0 0/18 IDC 19mm 2 3.38 - + -
Table 21: Group 1 patient and tumour data with sentinel lymph node marker


















1 58 1 0 0/12 IDC 9mm 1 2.18 - + -





3 57 1 0 0/10 IDC 9mm 1 2.18 - + -
4 71 1 0 0/10 IDC 20mm 3 4.4 - + -
5 78 1 0 0/13 tubular 20mm 1 2.4 - + -
6 62 1 1 1/17 IDC 16mm 2 4.32 - - -
7 55 1 0 0/10 IDC 9mm 2 2.18 - + -
8 70 1 0 0/21 IDC 34mm 3 4.68 - - -
9 36 1 0 0/16 IDC 15mm 2 3.3 - + -
10 52 1 1 0/12 IDC 10mm 1 2.2 - - -






12 37 1 1 1/17 IDC 15mm 3 5.3 - - -





14 52 1 1 20/23 IDC 30mm 3 6.6 + + -
15 61 1 0 0/13 IDC 40mm 1 2.8 - - -
16 72 1 0 0/14 IDC 15mm 2 3.3 - - -
17 75 1 1 11/16 IDC 20mm 1 4.4 + + -
18 52 1 1 0/12 IDC 30mm 3 4.6 - + -
19 58 2 1 0/13 IDC 20mm 1 3.4 + + +
20 81 1 1 0/23 IDC 35mm 2 4.7 + + +




22 54 1 0 0/6 IDC 15mm 2 3.3 - + -
23 36 1 1 6/21 IDC 32mm 3 6.64 + + -
24 82 2 0 0/6 IDC 17mm 2 3.34 - + -
25 84 1 1 1/13 IDC 47mm 3 5.94 + + -
26 50 1 0 1/15 IDC 15mm 2 4.3 - + -


















28 78 2 1 0/5 IDC 15mm 2 4.3 - - -
29 74 1 1 2/14 ILC 33mm 2 4.6 - + +
30 57 1 0 0/14 IDC 18mm 3 4.36 - + +
31 38 1 0 0/13 IDC 12mm 3 4.24 - + -
32 79 1 1 11/23 IDC 54mm 3 7.08 + + -
33 51 1 0 0/12 tubular 25mm 1 2.5 - + +
34 73 1 0 0/13 IDC 45mm 3 4.9 - - -
35 61 1 0 9/13 IDC 26mm 3 6.52 - - -
36 60 1 1 0/16 IDC 25mm 2 4.5 - + -
37 66 1 1 0/16 IDC 20mm 2 4.4 - + +
38 79 1 0 0/14 IDC 20mm 3 4.4 - + -
39 59 1 1 1/10 IDC 16mm 2 4.32 - + -
40 72 1 0 2/14 IDC 12mm 3 5.24 - - -
41 70 1 1 1/14 IDC 33mm 3 5.66 + + -
42 67 1 0 0/13 IDC 38mm 3 4.72 - + -
43 70 1 0/12 IDC 30mm 3 5.6 - +
+
-
44 65 1 1 0/8 IDC 13mm 3 5.26 + + -
45 56 1 0 0/11 IDC 22mm 2 3.44 - + -
46 53 1 10/22 ILC 32mm 2 5.64 + +
+
+
47 72 1 0 0/14 IDC 22mm 3 4.44 - + -
48 65 1 0 0/20 IDC 23mm 3 4.46 - - -
49 57 1 0 0/16 IDC 15mm 2 3.3 - + -
50 64 1 1 0/15 IDC 42mm 3 5.8 + + -
Table 22: Group 2 patient and tumour data with sentinel lymph node marker
expression (CK 19, MUC 1 and CEA)
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Table 23 below summarises the sensitivities, specificities and false negative rates of
marker expression by RT PCR compared with H&E histology for groups 1 and 2.
sensitivity specificity FNR
CK 19 group 1 90% 72.4% 10%
CK 19 group 2 62.5% 100% 37.5%
MUC 1 group 1 62.5% 55% 37.5%
MUC 1 group 2 91.3% 29.7% 8.7%
CEA group 1 12.5% 71.7% 87.5%
CEA group 2 26.1% 89.2% 73.9%
Table 23: Sensitivity, specificity and false negative rates for CK 19, MUC 1 and
CEA determined by RT PCR compared to H&E histology in group 1 and 2
FNR false negative rate
The best results were therefore achieved by CK 19 and MUC 1 however curiously MUC
1 expression was more sensitive in group 2 compared to group 1 which is contrary to
what one would expect. CK 19 achieved a respectable sensitivity of 90% when half
sentinel nodes were processed and a corresponding false negative rate of 10%. In both
groups CEA proved to be a very poor breast cancer marker particularly in terms of
sensitivity and false negative rate.
CK 19 expression agreed with the H&E histology most often in both group as shown in
table 24 below. Despite the poor results given above, CEA expression concorded with
H&E results in around two thirds of nodes in both groups. There were only just over a





Group 1 Group 2
CK 19 72% 85%
MUC 1 55.9% 53.3%
CEA 64.7% 65%
Table 24: Comparison ofmarker expression by RT PCR with H&E histology in
groups 1 and 2
When considering the upstaging potential of the marker expression results, group 1 was
upstaged to a greater degree than group 2 for CK 19 and CEA, as one would expect
however MUC 1 upstaged a greater percentage of nodes in group 2. MUC 1 produced
the greatest upstaging rate in both groups of nodes as shown in table 25 below.
Group 1 (n=68) Group 2 (n=60)
CK 19 expression 36.8% 25%
CK 19 %upstaged 23.5% 0%
MUC 1 expression 47% 78.3%
MUC 1 %upstaged 39.7% 43.3%
CEA expression 26.5% 16.7%
CEA % upstaged 26.5% 6.7%
Table 25: Expression and upstaging rates of sentinel lymph nodes by CK 19, MUC
1 and CEA RT PCR
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7.5. Concordance ofmarker expression
7.5.1. Group 1
The concordance between expression of CK 19 and MUC 1 was 72.1% with 49 out of 68
sentinel nodes being positive for both or negative for both. The remaining 19 sentinel
nodes expressed either CK 19 or MUC 1.
Comparing expression rates of CK 19 and CEA, there was 51.5% concordance with 35
out of 68 sentinel nodes expressing either both or neither marker. The remaining 43
nodes expressed either CK 19 or CEA.
The concordance between MUC 1 and CEA expression was 44.1% with 30 out of 68
sentinel nodes displaying the same expression pattern for the 2 markers. The remaining
38 sentinel nodes expressed either MUC 1 or CEA.
The combined expression patterns were the same for all 3 markers in 23 out of the 68
nodes (33.8%) with 20 sentinel nodes expressing none and 3 expressing all 3. Of the
nodes displaying no marker expression, there were 3 false negative cases where there
were El&E positive non sentinel lymph nodes. In the other 17 nodes where no marker
expression was found, all nodes were H&E negative. Of the nodes where all 3 markers
were found to be positive, H&E histology was also positive in 1 and in the other 2 the
sentinel node and all other axillary nodes were negative by H&E.
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CK 19
Figure 8: Venn diagram demonstrating marker expression by sentinel nodes from
group 1 patients
(20 nodes displayed no expression)
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7.5.2. Group 2
There was 46.7% concordance between CK 19 and MUC 1 expression, with 28 out of 60
nodes being positive for both markers or negative for both markers. The remaining 32
nodes all expressed MUC 1 but did not express CK 19. There were therefore no nodes
which expressed CK 19 without MUC 1 expression.
Comparing expression of CK 19 and CEA, there was concordance in 71.7% (43/60) of
sentinel nodes. In the remaining 17 nodes, some expressed CK 19 alone and some
expressed CEA alone.
Comparing expression ofMUC 1 and CEA, both nodes showed the same expression of
both markers in 23 cases (38.3% concordance). In the remaining 37 nodes, all showed
MUC 1 expression but no CEA expression. No nodes expressed CEA without MUC 1
expression.
Looking at the results for all 3 markers, there were only 17 out of 60 nodes (28.3%)
displaying the same expression pattern. In 13 nodes there was no expression of any
marker ofwhich 9 were H&E negative and 4 were H&E positive. In 4 nodes, which
were all H&E positive, all 3 markers were expressed. Of the 13 nodes negative for all 3
markers, 3 represented false negative nodes and so none of the PCR reactions had
upstaged these sentinel nodes and 2 other sentinel nodes were H&E positive. The
remaining 8 sentinel nodes with no marker expression were from patients in whom all
nodes were H&E negative. Using the results of the 3 PCR reactions together therefore
had incorrectly staged at least 5 patients (10%).
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CK 19
Figure 9: Venn diagram demonstrating marker expression by sentinel nodes from
group 2 patients
(13 nodes displayed no marker expression)
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7.6. Association of marker expression with Nottingham Prognostic Index
While the associations between the 3 markers and H&E histology were poor, inspection
of the data indicated a strong association between CK 19 expression and the Nottingham
Prognostic Index (NPI) values for both groups 1 and 2 (figure 10). In group 1, the mean
NPI value of CK 19 positive nodes was 4.3 compared to a mean value of 3.4 in the CK
19 negative nodes (p = 0.0046; unpaired t-test) and in group 2, the mean NPI of the CK
19 positive nodes was 5.7 compared to only 4.0 in the CK 19 negative nodes (p < 0.0001;
unpaired t-test). These data suggest that both tumour size and grade as well as the extent
of lymph node involvement contribute to the likelihood of detection of CK 19 in the
sentinel node.
GROUP 1 GROUP 2
P = 0.0046 (unpaired t-test)
-ve +ve
CK19
P < 0.0001 (unpaired t-test)
-ve +ve
CK19
Figure 10: Association between CK 19 expression and NPI in groups 1 and 2
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In contrast, the mean NPI values between patients with MUC 1 positive and MUC 1
negative sentinel nodes were not significantly different for either group 1 or 2 (p = 0.21





Sentinel node biopsy has emerged as an alternative to axillary dissection and sampling in
the staging of breast cancer however it is being performed by relatively few UK breast
surgeons regularly. In this country it remains largely trial-based and progress lags behind
many centres in the United States and Europe where the technique is now the standard of
care for early breast cancer where studies with medium term follow up have shown no
difference in regional recurrence or survival compared to axillary clearance.
One of the most important unanswered questions regarding the technique is how best to
analyse the sentinel node. Serial sectioning and immunohistochemistry identify disease
missed by standard H&E histology and RT PCR is a molecular technique which can
identify individual cancer cells. The success ofmolecular analysis depends on the
identification of a sensitive and specific breast cancermarker. So far such a marker or
panel ofmarkers has been elusive. There is conflicting evidence in the literature
regarding the sensitivity and specificity of all the putative breast cancer markers
described in lymph nodes of breast cancer patients and healthy controls. Until a reliable
marker or panel ofmarkers is identified RT PCR cannot replace histological assessment
of sentinel nodes. At present therefore only part of any sentinel node can be processed
for RT PCR analysis. If a sensitive and specific marker is identified then the clinical
significance of disease detected in this way could be addressed by long term follow up
studies.
Three putative breast cancer tumour antigens or 'markers' that have been previously
studied are CK 19, MUC 1 and CEA. One study found 100% expression of CK 19 by
primary breast tumours (Noguchi et al. 1996) however another study found that 10% of
breast cancers were CK 19 negative (Papadimitriou et al. 1993). The expression of MUC
1 by breast cancer cells appears to be universal however CEA expression is variable with
one study reporting 75% expression of CEA by primary breast tumours (Marchetti et al.
2001).
The aim of this thesis was to evaluate sentinel lymph nodes from breast cancer patients
by RT PCR looking for the presence of CK 19, MUC 1 and CEA. In particular different
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amounts of sentinel node tissue, half the node (from group 1 patients) versus a 4 pm
section (from group 2 patients), were processed for RT PCR. The RT PCR results were
correlated with H&E histology and this allowed the upstaging potential ofRT PCR to be
compared in the 2 tissue groups. One hypothesis proposed at the start of the study was
that the RT PCR results would correlate more closely with the H&E histology when the
results of all three markers were considered together rather than any of these markers
looked at in isolation. A discrepancy between H&E and RT PCR results was expected to
some degree due to the fact that the 2 techniques were performed on different parts of
each node. However RT PCR should be capable of detecting small disease foci in at least
a proportion of the H&E positive nodes and combining the results for all 3 markers
should maximise the correlation with H&E results. RT PCR should also hopefully up
stage some additional H&E negative sentinel nodes. As the RT PCRs for the 3 markers
were performed on the same tissue from each node, the expression rates of the 3 markers
should correlate closely with each other in the presence ofmetastatic disease if these
represent sensitive breast cancer markers. One would also expect higher expression rates
of the 3 markers the greater the amount of tissue processed.
As expected, there was no marker which was expressed by all H&E positive sentinel
nodes in either group. CK 19 expression was 90% sensitive in the sentinel nodes from
group 1 with a corresponding false negative rate of 10%. The results for this marker
were, as expected, poorer in group 2 where less tissue was processed (sensitivity 62.5%).
MUC 1 expression was 91.3% sensitive in the group 2 sentinel nodes but less sensitive in
group 1, contrary to that predicted. Expression of CEA was found to be very unreliable
with sensitivities of only 12.5% and 26.1% in groups 1 and 2 respectively. The
corresponding false negative rates were very high. One would have predicted that CEA
would give the poorest results given that it is the least widely expressed of the three
markers in breast cancers.
Comparing the expression rates of the different markers with each other, the results were
different between the 2 groups. The pairing that agreed the most in group 1 was CK 19
and MUC 1 (72.1% concordance) and in group 2 was CK 19 and CEA (71.7%
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concordance). In group 1 only about a third of the nodes (33.8%) displayed similar
expression rates ie all 3 positive or all 3 negative. Importantly, 3 sentinel nodes that were
false negative nodes based on H&E histology did not display expression of any of the 3
markers. In group 2, 28.3% of nodes were either positive or negative for all 3 markers.
In this group there were also 3 false negative sentinel nodes that did not express any
marker. Given that exactly the same tissue was examined for expression of the 3
markers, these figures confirm that the technique is unreliable in identifying metastatic
disease with respect to these particular markers. As discussed already the sensitivity rate
calculated for CEA would suggest that it is especially unreliable and therefore the poor
correlations between CEA and CK 19 and between CEA and MUC 1 are probably due
largely to CEA. CK 19 and MUC 1 expression rates agreed in nearly three quarters
(72.1%) of group 1 nodes but in less than half (46.7%) of group 2 nodes.
Similar expression rates were found in groups 1 and 2 for each marker. This is contrary
to one of the hypotheses set out at the start and is interesting given that the amount of
tissue processed for RT PCR was much greater for group 1 and therefore one would have
expected higher expression rates in this group. Group 2 contained a much higher
proportion (50%) ofhistologically node positive patients compared to group 1 (18%) and
this may explain why expression rates were not higher in group 1 compared to group 2.
The upstaging rates ofRT PCR however were greater for group 1 compared to group 2
for CK19 and CEA. For MUC 1 the upstaging rates were similar (39.7% versus 43.3%)
in groups 1 and 2.
Obviously the main objective of any type of analysis of axillary nodes is to identify
disease and therefore correctly stage the patient. It is therefore disappointing that a
technique that is capable of identifying individual tumour cells missed 3 false negative
sentinel nodes in both groups. There are various possible explanations for these false
negatives. Firstly, this study would suggest that none of the 3 markers studied was 100%
sensitive ie they were not expressed by breast cancer cells. This could have been further
validated by cither performing RT PCR for each marker on the primary tumours or by
using immunohistochemistry to look for marker expression in the sentinel nodes.
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Secondly, these cases may represent true cases of 'skip' metastases where the sentinel
node genuinely does not contain the disease but other axillary nodes, higher up in the
lymphatic chain, do harbour metastases. Thirdly, in some cases a sentinel node or nodes
may have been missed and therefore represent failures of the technique itself.
The sensitivity of RT PCR in this study has been discussed. The specificity of any
putative marker must also be considered in order that patients are not over staged by the
technique. The specificity rates calculated in this study are the percentages of nodes that
are H&E negative ('true negatives') that are correctly diagnosed by RT PCR. Clearly
there will be some sentinel nodes designated as negative by the H&E histology
performed which do harbour metastases. Some of these will have been upstaged by RT
PCR. The definition of a 'true negative' sentinel node and a 'true positive' sentinel node
is controversial but the only undisputed metastases of clinical significance are those
detectable by H&E and so the specificities calculated above are relevant based on the
literature to date. CK 19 expression reached 100% specificity in the sentinel nodes from
group 2 however expression of the same marker was only 72.4% specific in relation to
H&E histology in group 1. The specificities of CEA and MUC 1 in particular were
disappointing.
In order to determine the true specificity of a potential marker in identification of axillary
metastases, the expression rates in normal lymph nodes must be determined. Lymph
nodes from healthy controls were not included in this study and the literature is confusing
on this point. There are studies which have found both the presence and absence ofCK
19 and MUC 1 in control lymph nodes as discussed above. It therefore is possible that
some of the sentinel nodes that expressed the markers examined in this study represented
'false positives' due to expression by normal tissue in some individuals.
A significant association was found in both groups 1 and 2 between expression of CK 19
as determined by RT PCR and the NPI. This would suggest that patients with higher
grade and or larger tumours may be more likely to express CK 19 in their sentinel nodes.
The other 2 markers studied did not display a similar association.
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Included in this study were all patients presenting to the clinic with a clinically node
negative breast cancer and in fact the patients from group 2 included larger higher grade
cancers than would ordinarily be suitable for sentinel node biopsy. There was a high
proportion of node positive patients in this group - two thirds of the patients in whom a
sentinel node was not detected and around half of the patients in whom a sentinel node
was harvested. Clinical examination is notoriously inaccurate in the assessment of nodal
status as discussed above and the use of preoperative axillary ultrasound with FNA or
core biopsy of any abnormal looking nodes would have avoided so many node positive
patients undergoing the technique at all. This approach has developed over the last few
years and will increasingly be used to select patients for sentinel node biopsy. In 3 cases
where no sentinel node was identified the axilla was found to be extensively diseased and
this fits with the theory that blockage of lymphatic channels by tumour can hinder
dissemination of blue dye and colloid into the axillary lymphatics. These tumour factors
undoubtedly also contributed to the poor detection rate obtained.
All of the sentinel node biopsies carried out prospectively during this study for the group
2 patients were done using the combination of radioactive colloid with a pre-operative
lymphoscintigram and intra-operative blue dye. In this group of 50 patients in whom a
sentinel node was identified, we found that blue dye identified the sentinel node more
often than the radioactive colloid. In 48 patients the sentinel nodes were blue and in 26
out of 50 patients the sentinel nodes were hot. There were only 5 out of 60 sentinel nodes
that were hot and not blue. One study found that even following a positive scan, the
addition of blue dye increased the detection rate and decreased the false negative rate
(Degnim et al. 2005).
Intra-operative frozen section was performed on 103 sentinel lymph nodes with a false
negative rate of 21.2%, as expressed on a node basis. The sensitivity of frozen section in
identifying a positive sentinel node was 73%. This compares favourably with the
literature where sensitivities of between 59% and 79% have been reported as described
above. A positive frozen section allows axillary disease to be accurately diagnosed at the
time of surgery and therefore completion axillary surgery carried out at the same
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operation. A false negative result will subject some patients to a second procedure
however nothing has been lost by carrying out a frozen section. The average time taken
for the frozen section to be reported was 25 minutes and during this time the wide local
excision or mastectomy was carried out.
In conclusion, this study found that none of the 3 markers examined was sensitive or
specific enough to diagnose sentinel node metastases in breast cancer patients in clinical
practice. There was poor correlation between conventional H&E histology and the
expression ofCK 19, MUC 1 and CEA and more importantly poor correlation between
the expression of the individual markers suggesting that there was more to these
discrepancies than just sampling error. Contrary to one of the hypotheses of this study,
the expression of CK 19, MUC 1 and CEA did not depend on the amount of tissue
processed for RT PCR in this study however the upstaging rate was greater in the group
where half the node was processed compared to a 4pm section. All of the other
hypotheses have been proved.
The significant correlation that was found between CK 19 expression by the sentinel
nodes from both groups and NPI suggests that factors other than axillary node status, ie
tumour grade and or size, may contribute to the likelihood of CK 19 expression by the
sentinel node. Further work should therefore be done on this marker in particular to
further explore this association. Other markers may in the future prove to be more
reliable in determining the presence of sentinel node metastases. The clinical
significance of any such marker expression as detected by RT PCR could then be
evaluated by a long term follow up study.
Ill
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Switchboard: 0141 211 4000
Direct Dial:
Fax Number:
Sentinel Lymph Node biopsy in Patients with Breast Cancer.
Wc arc inviting you to participate in a research study involving Glasgow Koyal
Infirmary and The Western Infirmary. It is important that you understand why the
research is being done and what it will involve for you. Please take time to read the
following information carefully and do not hesitate to ask us about anything that you
are not clear about.
What is this study for?
Breast cancer is known to spread from the breast to the lymph glands under the arm.
At present patients diagnosed with breast cancer usually have these glands removed at
the time of the surgery to remove the tumour itself. The glands are then examined by
a pathologist who determines whether the cancer has spread to these glands and this is
important in deciding whether further treatment such as chemotherapy is necessary. It
has been demonstrated that cancer spreads to one gland (the sentinel node) first and
that if this is free from tumour then the other glands should also be free. In the future
we may be able to remove only the sentinel node if there is no sign of tumour spread
in this gland. This will avoid the possible side effects that can occur when all the
glands are removed such as ami swelling (lymphoedema). If you agree to participate
in this study this will not mean that you will obtain these benefits as we will still be
removing all of the glands from under your arm, as is current standard practice, after
identifying the sentinel node.
What do I do if I take part?
If you agree to take part you will be asked to sign a consent form. On the afternoon
before your surgery you will have an injection into your breast, around the tumour.
This will involve a small dose of radioactivity (the maximum dose given to you will
be 40MBq which is one hundred times lower than the dose used in some medical
investigations such as lung and bone scans). A short time after the injection you will
have a 'scan' which is completely painless and aims to detect glands under the arm to
which the radioactive injection has spread these 'hot spots' will be marked on the
skin. When you are under anaesthetic for your surgery some blue dye (not
radioactive) will be injected in a similar way and we will then use the radioactivity
and the dye to detect the sentinel lymph node. This node will then be removed and
sent to the pathologists for analysis. The surgery will then proceed in the standard
way ie the 'lump' or breast will be removed (as discussed with you before surgery)




IT SHOULD BE EMPHASISED THAT YOUR TAKING PART IS ENTIRELY-
VOLUNTARY, AND WHETHER YOU TAKE PART OR NOT WILL IN NO WAY
AFFECT YOUR CURRENT OR FUTURE TREATMENT.
What will happen to the sentinel node?
After the sentinel node has been removed, it will be examined using various
techniques which are designed to pick up very small traces of tumour spread. Some
of these techniques are currently not done routinely on lymph glands that are removed
from patients as this is not feasible with so many glands to examine. The sentinel
node will also undergo the routine pathology tests that are currently standard practice.
The other glands that are removed will also undergo standard examination.
Some tissue from your breast and from the sentinel and other lymph nodes will be
kept frozen in the hospital, AS IS DONE ROUTINELY FOR EVERY PATIENT AT
THE MOMENT.
What are the disadvantages and risks of taking part?
The only possible side effects are some pain associated with the first injection, done
while you are awake (the radioactivity) and slight temporary discolouration of your
skin and urine (for about 12 hours) this is completely harmless. The detection and
removal of the sentinel node adds about 15 minutes onto the time of your operation.
The steps described to do this arc in addition to standard treatment and so your
treatment will in no way be different from patients not participating in the study.
Will mv taking part in this study he confidential?
Any information that is collected from you during this study will be kept strictly
confidential.
• PLEASE UNDERSTAND THAT AT ANY TIME YOU CAN WITHDRAW
YOUR NAME FROM THIS STUDY WITHOUT AFFECTING YOUR CARE.
. THIS RESEARCH STUDY HAS BEEN REVIEWED BY THE GLASGOW
ROYAL INFIRMARY RESEARCH ETHICS COMMITTEE.
• THIS RESEARCH IS BEING CARRIED OUT IN THE DEPARTMENTS OF
SURGERY AND PATHOLOGY AT GLASGOW ROYAL INFIRMARY. NO
ONE INVOLVED IN THE RESEARCH GETS PAID ESPECIALLY TO DO
THIS STUDY.
• SHOULD YOU WISH TO OBTAIN ANY FURTHER INFORMATION,
PLEASE CONTACT MARGARET FALCONER AT GLASGOW ROYAL
INFIRMARY, TELEPHONE (0141) 211 5440.
Thank you for reading litis and taking pari in the study.
Version no. 2, November 2000
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Appendix II - Patient consent form







Patient Identification Number for this trial:
CONSENT FORM
The use of multiple sectioning, immunohistochemistrv and RT-PCR to
detect metastases in the sentinel Ivmph nodes of patients with breast
cancer
Name of researcher: Miss Margaret Falconer, Professor Tim Cooke, Miss J Doughty, Dr JJ Going
Please initial box
1. I confirm that I have read and understand the information sheet dated November 2000
(version ..No. 2...) for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any time,
without giving any reason, without my medical care or legal rights being affected.
3. I understand that sections of any of my medical notes may be looked at by responsible
individuals from regulatory authorities where it is relevant to my taking part in research
I give permission for these individuals to have access to my records.
4. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent
(if different from researcher)
Date Signature
Researcher Date Signature




Appendix III - Conference proceedings
1. Upstaging of sentinel nodes in breast cancer by cytokeratin 19 RT-PCR
ME MacLean. J Edwards, JJ Going, TG Cooke, JMS Bartlett
Poster presentation, 25th annual San Antonio Breast Cancer Symposium, Texas
December 2002
2. Use of reverse transcription PCR to detect cytokeratin 19 expression in sentinel
nodes of patients with breast cancer.
ME MacLean. J Edwards, JJ Going, TG Cooke, JMS Bartlett
Oral presentation, 3rd European Breast Cancer Conference, Barcelona
March 2002
3. Intra-operative frozen section reliably predicts sentinel node status in patients
with breast cancer.
ME MacLean. CRWilson, MM Flett, JJ Going, JMS Bartlett, TG Cooke
Oral presentation, 24th annual San Antonio Breast Cancer Symposium, Texas
December 2001
4. Intra-operative frozen section reliably predicts sentinel node status in breast
cancer
ME MacLean. CRWilson, MM Flett, JJ Going, TG Cooke
Oral presentation, West of Scotland Surgical Society annual meeting
October 2001
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5. Intra-operative frozen section reliably predicts sentinel node status in patients
with breast cancer.
ME MacLean. JJ Going, CRWilson, MM Flett, TG Cooke
Oral presentation, 7th Nottingham International Breast Cancer Conference,
September 2001
6. Intra-operative frozen section reliably predicts sentinel node status in patients
with primary breast cancer
ME MacLean. JJ Going, MM Flett, CRWilson, TG Cooke




Appendix IV - Publications
1. Intra-operative frozen section reliably predicts sentinel node status in patients
with breast cancer.
MacLean ME, Wilson CR, Flett MM, Going JJ, Bartlett JMS, Cooke TG.
Breast Cancer Research and Treatment 2001; 69(3): 217
(Abstract)
2. Intra-operative frozen section reliably predicts sentinel node status in patients
with primary breast cancer
ME MacLean, JJ Going, MM Flett, CRWilson, TG Cooke
British Journal of Surgery 2001: 88 (SI): 40
(Abstract)
3. Intra-operative frozen section reliably predicts sentinel node status in patients
with breast cancer.
ME MacLean, JJ Going, CR Wilson, MM Flett, TG Cooke
European Journal of Cancer 2001: 37(S5): 18
(Abstract)
4. Use of reverse transcription PCR to detect cytokeratin 19 expression in sentinel
nodes of patients with breast cancer.
ME MacLean, J Edwards, JJ Going, TG Cooke, JMS Bartlett.
European Journal of Cancer 2002: 38 (S3): S156
(Abstract)
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